Queensland Clinical Guidelines

Translating evidence into best clinical practice

Maternity and Neonatal Clinical Guideline

Primary postpartum haemorrhage (PPH)



Document title:	Primary postpartum haemorrhage (PPH)
Publication date:	August 2024
Document number:	MN24.1-V12-R29
Document supplement:	The document supplement details development processes and implementation activities, and is integral to and should be read in conjunction with this guideline
Amendments:	Full version history is supplied in the document supplement
Amendment date:	November 2024
Replaces document:	MN24.1-V11-R29
Author:	Queensland Clinical Guidelines
Audience:	Health professionals in Queensland public and private maternity and neonatal services
Review date:	August 2029
Endorsed by:	Queensland Clinical Guidelines Steering Committee Queensland Maternity and Neonatal Clinical Network
Contact:	Email: <u>Guidelines@health.qld.gov.au</u> URL: <u>www.health.qld.gov.au/qcg</u>



Acknowledgement

The Department of Health respectfully acknowledges the Traditional Owners and Cultural Custodians of the lands, waters and seas across Queensland. We pay our respects to Elders past and present, while recognising the role of current and future leaders in shaping a better health system.

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making, including the right to decline intervention
 or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

Recommended citation: Queensland Clinical Guidelines. Primary postpartum haemorrhage (PPH) Guideline No. MN24.1-V12-R29 Queensland Health. 2024. Available from: <u>http://www.health.qld.gov.au/qcg</u>


© State of Queensland (Queensland Health) 2024



This work is licensed under a Creative Commons Attribution-Non-commercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email <u>Guidelines@health.qld.qov.au</u>, phone (07) 3131 6777. For permissions beyond the scope of this licence, contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au


Flowchart: Initial response to postpartum haemorrhage (PPH)



EUA: examination under anaesthetic, FBC: full blood count, IDC: indwelling catheter, IM: intramuscular, IV: intravenous, MHP: major haemorrhage protocol, OT: operating theatre, PE: pulmonary embolism, PoC: point of care, RBC: red blood cells, ROTEM[®]/TEG[®]: types of blood clotting analysers, RSQ: Retrieval Services Queensland, SpO₂: saturation of oxygen, VTE: venous thromboembolism, <: less than, >: greater than

Flowchart: F24.1-1-V6-R29

Flowchart: Major haemorrhage protocol (MHP)



Flowchart: F24.1-2-V5-R29

Table of Contents

Definitions	7
1 Introduction	8
1.1 PPH Definition	8
1.2 Incidence of PPH in Queensland	8
1.3 Aetiology	9
1.4 Clinical standards	9
2 Risk factors	10
3 Antenatal risk management	.11
4 Intrapartum risk management	.12
4.1 Third stage	
4.2 Prophylactic uterotonics	
4.2.1 Oxytocin	
4.2.2 Syntometrine [®]	
4.2.3 Carbetocin	
4.2.4 Misoprostol	
5 Fourth stage	
6 Recognition of PPH	
6.1 Assessment of blood loss	
6.2 Haemodynamic compromise	
7 Responding to PPH	
7.1 Resuscitation	
7.2 Tranexamic acid	
7.3 Point of care blood clotting analysers	
7.4 Support during PPH	.20
8 Management of Four Ts	
8.1 Tone	
8.1.1 First line pharmacological therapy for uterine atony	
8.1.2 Second line pharmacological therapy for uterine atony	
8.2 Trauma	
8.2.1 Genital trauma	
8.2.2 Cervical trauma	
8.2.3 Uterine rupture 8.2.4 Uterine inversion	
8.2.4 Oterine inversion	
8.4 Thrombin 8.4.1 Coagulopathy principles	
8.4.2 Correction of coagulopathy	
8.4.3 Laboratory values	
	.29
9 Intractable bleeding	-
9.1 Mechanical treatment of intractable bleeding	
9.2 Surgical treatment of intractable bleeding	
10 Major haemorrhage	
10.1 Major haemorrhage protocol considerations	
11 Women who cannot receive a blood transfusion	
12 Postnatal care after PPH	
References	
Appendix A: Uterine atonia interventions	
Appendix B: Surgical ligation procedures	
Appendix C: Prophylactic uterotonics	
Appendix D: Drugs and blood products for PPH treatment	
Appendix E: PoC testing obstetric specific reference ranges	
Acknowledgements	46

List of Tables

Table 1. Postpartum haemorrhage definitions	8
Table 2. Incidence of PPH in Queensland	
Table 3. Aetiology of PPH	
Table 4. Clinical standards	
Table 5. Risk factors for PPH	
Table 6. Antenatal risk management	
Table 7. Intrapartum risk management	12
Table 8. Third stage risk management	
Table 9. Oxytocin	
Table 10. Syntometrine [®]	14
Table 11. Carbetocin	
Table 12. Misoprostol	
Table 13. Fourth stage management	16
Table 14. Assessment of blood loss	17
Table 15. Clinical signs and symptoms of blood loss	17
Table 16. Resuscitation	
Table 17. Tranexamic acid	
Table 18. Point of care blood clotting analysers	
Table 19. Support during PPH	
Table 20. Oxytocin	
Table 21. Ergometrine	
Table 22. Misoprostol	.21
Table 23. 15-methyl prostaglandin F2 alpha (carboprost)	.21
Table 24. Genital trauma	. 22
Table 25. Cervical trauma	
Table 26. Uterine rupture	
Table 27. Uterine inversion	
Table 28. Tissue	
Table 29. Coagulopathy principles	
Table 30. Correction of coagulopathy	
Table 31. Laboratory values	
Table 32. Blood cell replacement	. 29
Table 33. Intractable bleeding	
Table 34. Mechanical procedures	. 30
Table 35. Surgical procedures	. 31
Table 36. MHP considerations	. 32
Table 37. Blood products declined	. 33
Table 38. Postnatal care	

Abbreviations

Arterial blood gas
Activated partial thromboplastin time
Controlled cord traction
Confidence interval
Caesarean section
Haemoglobin
Full blood count
Fresh frozen plasma
General Practitioner
International normalised ratio
Major haemorrhage protocol (also known as massive transfusion protocol or massive haemorrhage protocol)
Odds ratio
Operating theatre
Placenta accreta spectrum
Point of care
Postpartum haemorrhage
Prothrombin time
Red blood cells
Risk ratio
Retrieval Services Queensland
Venous thromboembolism

Definitions

Critical bleeding	Defined as life threatening major haemorrhage that will likely result in the need for massive transfusion. ^{1,2}
Full chemistry profile	Also referred to as a 'Chem20' in Auslab. Includes: sodium, potassium, chloride, bicarbonate, creatinine, urea, glucose, total protein, albumin, total bilirubin, direct bilirubin, urate, alt, AST, ALP, GGT, LD, calcium, phosphate, magnesium, anion gap, osmolality, urea/creatinine ratio, globulin, albumin-corrected calcium, eGFR (patients over 18 years).
Massive transfusion	In adults, is defined as transfusion of greater than or equal to 5 units of red blood cells in four hours. ¹
Placenta accreta spectrum	A spectrum of abnormal placentation disorders, occurring when the placenta infiltrates deeply into the muscle layer of the uterus. Includes placenta accreta, placenta increta and placenta percreta. ^{3,4}
Secondary postpartum haemorrhage	Excessive bleeding occurring between 24 hours and 6 weeks post birth. ²
Woman/women	QCG recognise that individuals have diverse gender identities. In QCG documents, although the terms <i>woman</i> and <i>women</i> are used, these guidelines are inclusive of people who are pregnant or give birth and who do not identify as female. ^{5,6}

1 Introduction

Primary postpartum haemorrhage (PPH) is the most common form of obstetric haemorrhage and is a leading cause of maternal morbidity and mortality in Australia⁷ and worldwide.^{8,9} In developed countries there is a trend of increasing PPH that has not been completely explained by the changing risk profile of women.^{10,11} Obstetric haemorrhage (which includes antepartum and postpartum haemorrhage) was responsible for 11 Australian maternal deaths between 2012–2021 (a maternal mortality ratio of 0.4 per 100,000).¹²

1.1 **PPH Definition**

Although there is no single definition, primary postpartum haemorrhage is termed as excessive bleeding in the first 24 hours post birth. PPH can be classified using definitions in Table 1. Postpartum haemorrhage definitions. In an emergent situation, recognition most commonly occurs through estimation of blood loss volume and changes in the haemodynamic state.

Aspect	Definition
Blood loss volume	 Blood loss of 500 mL or more^{2,8,9} Severe: 1000 mL or more^{2,13} Major haemorrhage: 2500 mL or more^{2,8} Queensland perinatal data collection, categorises PPH blood volume as: 500–999 mL 1000–1499 mL 1500 mL or more
Haemodynamic compromise	 Assessed based on observation of clinical signs-use clinical judgement Manifests as worsening tachycardia, hypotension and reduced urine output Requires an intervention (e.g. intravenous fluids) Due to frequent underestimation of blood loss, PPH may first be detected through haemodynamic compromise^{7,13} Signs of compromise may not be evident until large volumes of blood are lost^{2,3}
Haemoglobin (Hb)	 Retrospectively diagnosed as a 10 g/L (10%) drop in postpartum Hb (an equivalent measure for 500 mL blood loss)¹⁴
International Classification of Diseases 11 th revision (ICD-11)	 Haemorrhage after delivery of fetus or infant Includes sub-classifications of¹⁵: Third stage: caused by uterine atony, trauma, retained placenta, or coagulopathy Other immediate: within first 24 hours after completion of third stage of labour, caused by uterine atony, trauma, retained placenta, or coagulopathy Postpartum coagulation defects: caused by coagulation defects during the postpartum period

Table 1. Postpartum haemorrhage definitions

1.2 Incidence of PPH in Queensland

Table 2. Incidence of PPH in Queensland

	PPH (mL)	2017	2018	2019	2020	2021
Total births		59,399	59,644	59,559	58,731	62,482
Total PPH rate (%)		9.12%	10.17%	8.5%	8.75%	8.12%
Vaginal birth	500–999	2,118	2,426	2,041	2,087	1,947
	≥ 1000	1,615	*1,720	1,549	1,596	1,431
Caesarean section (CS) birth	500–999	985	1,151	747	687	852
	≥ 1000	702	769	726	769	843
PPH plus blood transfusion		627	616	560	606	600

*Includes 3 PPH with volume not stated. Source: PDC data extracted March 2024

1.3 Aetiology

The common causes of PPH are referred to as the 'Four Ts'. More than one cause may be present (e.g. tone and tissue).

Cause (% of PPH)	Presentation
Tone (70-80%)	Atonic uterus
Trauma (20%)	 Lacerations of the cervix, vagina and perineum, including episiotomy Extension lacerations at CS Uterine rupture or inversion Non-genital tract trauma (e.g. subcapsular liver rupture)
Tissue (10%)	 Retained products, placenta (cotyledon or succenturiate lobe), membranes or clots, abnormal placenta
Thrombin (<1%)	Coagulation abnormalities

1.4 Clinical standards

Table 4. Clinical standards

Aspect	Consideration
Emergency systems	 Establish local protocols and systems to facilitate^{1,16}: A multidisciplinary response (e.g. medical emergency team (MET) call) Major haemorrhage protocol (MHP) activation Access to emergency blood products and equipment Relevant specialist advice
Low resource settings	 Where access to resources is limited (e.g. human resources, equipment, blood products, transfer options to higher level services): Store and maintain access to fibrinogen concentrate (minimum 4 g) Rotate stock with larger facilities to minimise wastage from expiration Consider earlier triggers for activating requests for support (e.g. Retrieval Services Queensland (RSQ), blood products) Consider use of uterotonics that do not require cold-chain storage such as carbetocin and misoprostol Refer to Section 4.2 Prophylactic uterotonics
Clinical education	 Adherence with evidence informed guidelines reduces maternal morbidity¹⁷ Implement regular multidisciplinary practice drills and simulation training to improve^{16,18}: Identification of PPH Assessment of blood loss (e.g. volume, speed and nature) Signs of haemodynamic compromise Emergency response to PPH Emergency response to maternal collapse Engage staff in clinical event debriefing after a PPH^{19,20} Encourage staff training in debriefing to support effective communication with the woman and her family
Reporting and documentation	 Notify of PPH via local adverse event reporting systems Use an approved maternity early warning tool (e.g. Q-MEWT), clinical pathway or proforma that¹⁶: Standardises and records clinical response and care Enables data collection and clinical audit
Standard care	 Refer to Queensland Clinical Guideline: <u>Standard care</u>²¹ for care considered 'usual' or 'standard' Includes for example: privacy, consent, decision making, sensitive communication, medication administration, staff education and support, culturally appropriate care

2 Risk factors

Wherever possible, identify PPH risk factors in advance. The magnitude of risk attributable to each factor varies across reports²² and there may be unknown, interdependent and/or synergistic effects involved. Many women will experience a PPH with no identifiable risk factors.^{3,14}

Table 5.	Risk fac	ctors for	PPH
----------	----------	-----------	-----

Antenatal risk factor	Detail of study	OR	95% CI	Aetiology
Maternal age	> 35 years	1.1	1.0 to 1.3 ²³	Tone
	Asian	1.31	1.01 to 1.72 ²⁴	Tone
Ethnicity	Sub-Saharan Africa	1.54	1.10 to 2.16 ²⁴	Trauma
	Pacific Island	1.75	1.43 to 2.15 ²⁵	Trauma
Parity	> 3	1.47	1.01 to 2.13 ²⁴	Tone
Prior uterine surgery	Not specified	3.38	1.60 to 7.14 ²⁴	Trauma
	No praevia	0.61	0.60 to 0.62 ²⁶	Trauma
Prior caesarean section (CS)	With praevia or PAS	5.58	5.35 to 5.81 ²⁶	Trauma Tone Thrombin
Placenta praevia	No prior CS	2.39	2.31 to 2.47 ²⁶	Tissue Tone Thrombin
Antepartum haemorrhage or placental abruption		2.07	2.02 to 2.12 ²⁶	Tissue Tone Thrombin
Previous PPH	> 1000 mL	3.3	3.0 to 3.5 ²⁷	Tone
	> 1500 mL	6.42	3.9 to 10.6 ²⁴	
Uterine fibroid	Fibroid tumours	2.43	1.99 to 2.97 ²⁷	Tone
Pre-eclampsia	Severe features	2.90	2.79 to 3.03 ²⁶	Thrombin
Obesity	Body mass index > 35	2.3	1.3 to 3.6 ²⁸	Tone
Anticoagulants		4.66	2.81 to 7.73 ²⁴	Thrombin
	Hb ≤ 9 g/L	4.11	2.76 to 6.1324	
Anaemia	10 g/L reduction in antenatal Hb	1.36	1.27 to 1.46 ²⁹	Tone
Artificial reproductive technology	IVF/ICSI	1.8	1.5 to 2.1 ²³	_
Gestational diabetes		1.56	1.05 to 2.3124	Tone
Multiple pregnancy		2.1	1.5 to 2.8 ²³	Tone
Polyhydramnios		1.3	1.27 to 1.35 ²⁶	Tone
Drug induced atonia	Magnesium sulphate SSRI use in pregnancy Nifedipine	1.4 1.34 N/A	1.11 to 1.77 ³⁰ 1.24 to 1.44 ³¹	Tone
Macrosomia	> 4000 g	2.4	2.2 to 2.6 ²³	Tone Trauma
Inherited bleeding disorder	VWD ³² /Platelet function disorders	N/A	2.2 10 2.0	Thrombin
Intrapartum risk factor	Detail of study	OR	95% CI	Aetiology
Oxytocin use in labour		1.97	1.52 to 2.5733	Tone
Prolonged second stage	≥ 2 hours	1.9	1.2 to 2.9 ¹⁶	Tone
Prolonged third stage	≥ 30 mins	3.59	1.60 to 8.03 ³⁴	Tone
Retained placenta		32.9	26.2 to 41.5 ²³	Tissue
Manual removal of placenta		29.3	28.8 to 29.811	Tissue
Assisted vaginal birth		1.0.1		Trauma
Accession a vaginar birtin		1.31	1.29 to 1.33''	riauna
	All	<u>1.31</u> 1.6	1.29 to 1.33 ¹¹ 1.4 to 1.7 ²³	Tradilla
CS birth	All Emergency (before or during labour)		1.29 to 1.33 ¹¹ 1.4 to 1.7 ²³ 1.9 to 2.3 ²³	Trauma
CS birth	Emergency (before or	1.6	1.4 to 1.7 ²³	Trauma
	Emergency (before or during labour)	1.6 2.1	1.4 to 1.7 ²³ 1.9 to 2.3 ²³	
CS birth	Emergency (before or during labour) Episiotomy	1.6 2.1 1.64	1.4 to 1.7 ²³ 1.9 to 2.3 ²³ 1.62 to 1.66 ¹¹	Trauma
CS birth Perineal trauma	Emergency (before or during labour) Episiotomy	1.6 2.1 1.64 1.71	1.4 to 1.7 ²³ 1.9 to 2.3 ²³ 1.62 to 1.66 ¹¹ 1.66 to 1.76 ¹¹	Trauma Trauma
CS birth Perineal trauma Uterine rupture	Emergency (before or during labour) Episiotomy	1.6 2.1 1.64 1.71 23.1	1.4 to 1.7 ²³ 1.9 to 2.3 ²³ 1.62 to 1.66 ¹¹ 1.66 to 1.76 ¹¹ 20.4 to 26.2 ³⁵	Trauma Trauma Trauma
CS birth Perineal trauma Uterine rupture General anaesthesia	Emergency (before or during labour) Episiotomy > 2nd degree tear PROM	1.6 2.1 1.64 1.71 23.1 2.90 1.51	1.4 to 1.7 ²³ 1.9 to 2.3 ²³ 1.62 to 1.66 ¹¹ 1.66 to 1.76 ¹¹ 20.4 to 26.2 ³⁵ 1.90 to 4.50 ¹⁶	Trauma Trauma Trauma
CS birth Perineal trauma Uterine rupture	Emergency (before or during labour) Episiotomy > 2nd degree tear PROM Temp > 38 ^o C in labour	1.6 2.1 1.64 1.71 23.1 2.90 1.51 2.53	$\begin{array}{c} 1.4 \text{ to } 1.7^{23} \\ 1.9 \text{ to } 2.3^{23} \\ \hline 1.62 \text{ to } 1.66^{11} \\ 1.66 \text{ to } 1.76^{11} \\ \hline 20.4 \text{ to } 26.2^{35} \\ \hline 1.90 \text{ to } 4.50^{16} \\ \hline 1.19 \text{ to } 1.93^{24} \\ 1.78 \text{ to } 3.58^{24} \end{array}$	Trauma Trauma Trauma Tone
CS birth Perineal trauma Uterine rupture General anaesthesia Infection	Emergency (before or during labour) Episiotomy > 2nd degree tear PROM	1.6 2.1 1.64 1.71 23.1 2.90 1.51	1.4 to 1.7^{23} 1.9 to 2.3^{23} 1.62 to 1.66^{11} 1.66 to 1.76^{11} 20.4 to 26.2^{35} 1.90 to 4.50^{16} 1.19 to 1.93^{24} 1.78 to 3.58^{24} Not available	Trauma Trauma Trauma Tone Tone/Thrombin
CS birth Perineal trauma Uterine rupture General anaesthesia	Emergency (before or during labour) Episiotomy > 2nd degree tear PROM Temp > 38 ^o C in labour	1.6 2.1 1.64 1.71 23.1 2.90 1.51 2.53 2.5 ²	$\begin{array}{c} 1.4 \text{ to } 1.7^{23} \\ 1.9 \text{ to } 2.3^{23} \\ \hline 1.62 \text{ to } 1.66^{11} \\ 1.66 \text{ to } 1.76^{11} \\ \hline 20.4 \text{ to } 26.2^{35} \\ \hline 1.90 \text{ to } 4.50^{16} \\ \hline 1.19 \text{ to } 1.93^{24} \\ 1.78 \text{ to } 3.58^{24} \end{array}$	Trauma Trauma Trauma Tone

CI: confidence interval, ICSI: Intracytoplasmic sperm injection, IVF: In vitro fertilization, N/A: Not available, OR: odds ratio, PROM: prolonged rupture of membranes, SSRI: selective serotonin reuptake inhibitors, VWD: Von Willebrand Disease

3 Antenatal risk management

Table 6. Antenatal risk management

Clinical aspects	Risk reduction measures
Assessment	 Recommend routine blood group and antibody testing³⁷ If antenatal risk factors for PPH identified: Highlight in the health record Consult/refer to obstetrician as required Involve the woman in a plan of care aimed at mitigating risk Refer to Section 11 Women who cannot receive a blood transfusion
Anaemia	 In Queensland, the normal Haemoglobin (Hb) reference range for 25–42 weeks gestation is 98–137 g/L³⁸ A low antenatal Hb has a strong association with PPH²⁹ Screen for anaemia as per routine antenatal schedule^{37,39} Assess Hb levels against gestation-related thresholds³⁷ Investigate ferritin levels as indicated⁴⁰ Offer advice about minimising anaemia (e.g. dietary information) Optimise Hb antenatally Women with anaemia cannot tolerate the same volume of blood loss as healthy women²⁹ If iron deficiency anaemia diagnosed, recommend iron therapy in pregnancy⁴⁰ First line treatment is with oral iron supplements⁴⁰ If indicated (e.g. poor adherence to recommendations or absorption of oral iron, iron deficiency anaemia present in third trimester), consider intravenous iron therapy^{40,41} Routine use of erythropoiesis stimulating agents is not recommended Consider only in selected women at high risk of substantial blood loss in combination with iron therapy and in consultation with haematologist^{2,41} If antenatal blood transfusion is required, ensure blood is cytomegalovirus (CMV) antibody negative (i.e. specify on request form)
Maternal blood disorders	 Involve specialist physician to^{2,41}: Optimise/stabilise coagulation profile prior to birth Advise on birth options (e.g. mode of birth) Seek anaesthetic opinion regarding options for analgesia during labour and birth
Abnormal placentation	 Increased CS rates have contributed to an increase in occurrence of abnormal placentation⁴² Perform an ultrasonographic examination and, if indicated, magnetic resonance imaging⁴ Determine placental site and if abnormal placental adhesion present (e.g. placenta accreta spectrum)⁴² If abnormal placentation evident, consult obstetrician and involve multidisciplinary team in preoperative planning⁴: Timing and location of birth Presence of consultant obstetrician and anaesthetist, radiology expertise, neonatologist and cell salvage at birth Type of anaesthesia Availability of blood and blood products Availability of postoperative intensive care bed Discuss plan of care and possible interventions with the woman prior to birth (e.g. hysterectomy, intervention radiology, leaving placenta in place)

4 Intrapartum risk management

Table 7	Intranartur	n risk manage	mont
Table 7	. muapanun	n nsk manage	ment

Aspects	Risk reduction measures
Care planning	 Review antenatal and intrapartum risk factors on presentation for birth Continually assess and alter recommended management as risk factors arise or change during labour^{43,44} Discuss preferences and plan for management of third stage^{16,43} Refer to Section 4.1 Third stage
Maternal blood considerations	 If clinically significant antibodies are present, request cross-matched blood on presentation for birth If maternal blood disorder, anticipate the risk of bleeding and engage multidisciplinary team^{2,41} Seek specialist care on presentation for birth as indicated (e.g. obstetrician, anaesthetist, haematologist) Early consultation with laboratory/blood bank
Vaginal birth	 Consider each woman's risk profile for PPH when recommending care during labour Use of an oxytocin infusion in labour and high cumulative doses associated with an increased risk of PPH^{45,46} Maternal position during labour does not influence the risk of PPH⁴⁷ If PPH risk factors identified [refer to Section 2 Risk factors]: Consider prophylactic IV access Lack of evidence regarding which labouring women should be offered an intravenous cannula⁴⁸ Consider the significance of PPH risk factor(s) identified and use clinical judgement Consider collection of Full blood count (FBC) and group and hold If vaginal birth after CS (VBAC), increased risk of uterine rupture and PPH^{49,50} Monitor for early signs of uterine rupture [refer to Table 26. Uterine rupture] Refer to Queensland Clinical Guideline: Vaginal birth after caesarean (VBAC)⁵¹
Caesarean section (CS)	 Establish IV access Confirm recent blood results (i.e. less than 72 hours old), or collect if necessary: FBC Group and hold (if no valid group and hold available) Cross-match in selected circumstances if indicated Experienced obstetrician required if: Increased risk of extensions or lacerations (e.g. second stage CS, unsuccessful assisted vaginal birth) Malpresentation Evidence of abnormal coagulation History of previous PPH or other significant risk factors
Induction of labour (IOL) Intraoperative cell salvage	 On admission, confirm routine blood results are less than 72 hours old or collect if necessary: FBC Group and hold Refer to Queensland Clinical Guideline: <u>Induction of labour</u>⁵² If equipment and perfusionist available, recommend for women at high risk of severe PPH, experiencing major haemorrhage, or when RBC are

4.1 Third stage

Refer to Queensland Clinical Guideline: <u>Normal birth</u>⁵³ for routine management of third stage.

Aspects	Risk reduction measures
Uterotonic	 Recommend a prophylactic uterotonic to all women giving birth Reduced risk of PPH when compared with no uterotonic^{8,43,54} Refer to Section 4.2 Prophylactic uterotonics Refer to Appendix C: Prophylactic uterotonics
Cord clamping	 Delayed cord clamping (not earlier than one minute after birth) is recommended for all births¹⁶ and has not been shown to increase the risk of PPH⁵⁵
Controlled cord traction (CCT)	 CCT as part of active/modified active management of third stage may reduce the incidence of PPH, the duration of third stage, and need for manual removal of placenta⁵⁶
Physiological management	 Provide information about the risks and benefits of physiological versus active management of third stage Recommend uterotonic if⁴³: Excessive bleeding Delay in placental birth greater than one hour Woman requests to shorten third stage
Not beneficial for PPH prevention	 Nipple stimulation and/or early breastfeeding May increase uterine activity but has not been shown to reduce bleeding or incidence of PPH⁵⁷

Table 8. Third stage risk management

4.2 Prophylactic uterotonics

Refer to Appendix C: Prophylactic uterotonics

4.2.1 Oxytocin

Table 9. Oxytocin

Aspect	Consideration
Evidence summary	 In most circumstances, is the prophylactic uterotonic of choice^{10,13} Effective in reducing blood loss at birth and for PPH prevention when compared with no uterotonic^{8,58} Administered before versus after the birth of placenta showed no significant difference to PPH greater than 500 mL⁵⁹ Route of administration For vaginal birth: When compared with IM, IV oxytocin reduces the risk of PPH, need for blood transfusion⁶⁰⁻⁶², and incidence of retained placenta⁶¹ No significant difference in side effects (e.g. hypotension and tachycardia) between routes^{60,61} For CS birth: Limited evidence for optimal IV dosing regimen^{63,64} If cardiovascular compromise exists (e.g. hypovolaemia, shock, cardiac disease) IV use may result in transient haemodynamic instability^{61,65}: Marked hypotension, tachycardia, chest pain and electrocardiogram changes
Recommendation	 If vaginal birth without IV access: Oxytocin 10 International units IM^{16,43} If vaginal birth with IV access: Oxytocin 10 International units IV injected slowly over 3–5 minutes⁶⁶ is recommended in preference to IM^{2,61} For CS birth: Oxytocin 3–5 International units IV over 1–2 minutes^{16,64,67} Monitor for haemodynamic impact⁶⁷ Avoid rapid IV bolus administration If cardiovascular risks present, use caution with IV administration^{2,61}

4.2.2 Syntometrine®

Ampoule contains oxytocin 5 International units and ergometrine maleate 500 micrograms per mL.68

Table 10. Syntometrine®

Aspect	Consideration
Evidence summary	 Compared with oxytocin Reduced need for additional uterotonics and small (4%)⁵⁴ reduction in risk of PPH greater than 500 mL^{54,69} Increased nausea, vomiting, headache, diarrhoea, and hypertension^{9,43,69} Contraindicated for women with severe hypertension, pre-eclampsia, eclampsia, or severe cardiac, hepatic, renal or peripheral vascular disease^{43,70}
Recommendation	 If no PPH risk factors identified: Not recommended for routine use^{13,71} If PPH risk factors identified [refer to Section 2 Risk factors]: Individually assess the potential benefit of a small reduction in blood loss versus increased risk of adverse effects associated with use^{16,43} If syntometrine[®] not appropriate, consider carbetocin in preference to oxytocin due to increased half-life and duration of action and similar side effect profile to oxytocin⁶⁹ [refer to Table 11. Carbetocin] Offer antiemetics⁴³ to woman having syntometrine[®]

4.2.3 Carbetocin

Table 11.	Carbetocin
-----------	------------

Aspect	Consideration
Evidence summary	 Indicated for PPH preventative use after CS or vaginal birth⁷² Compared with oxytocin: Vaginal birth Comparable for PPH prevention and reducing use of additional uterotonics^{69,73,74} CS birth Similar or better outcomes for PPH prevention^{43,54} Less need for additional uterotonics (e.g. oxytocin infusion)^{54,75,76} Reduction in PPH greater than 500 mL and severe PPH greater than 1000 mL⁵⁴ Insufficient evidence regarding use with general anaesthetic (GA)⁷² Compared with syntometrine[®]: No significant difference, both considered effective for prevention of PPH⁶⁹ Side effect profile like oxytocin⁷⁴
Recommendation	 If vaginal birth and cold-chain storage of oxytocin can be guaranteed (e.g. hospital setting): Routinely use oxytocin in preference to carbetocin^{9,13} If vaginal birth and cold-chain storage of uterotonic cannot be guaranteed: Carbetocin is an effective alternative uterotonic IM is preferred route of administration⁷² If CS birth under regional anaesthetic: IV carbetocin may be considered as a cost effective uterotonic^{43,44} If CS birth under general anaesthetic: Not recommended due to insufficient evidence Single dose only—not for repeated use⁷²

4.2.4 Misoprostol

Table 12. Misoprostol

Aspect	Consideration
Evidence summary	 Not listed for use as preventative uterotonic in List of approved medicines (LAM)⁷⁷ Not recommended if alternative injectable uterotonics are available^{71,78} Compared to no uterotonic, is effective for prevention of PPH⁵⁴ Compared with oxytocin, sole use of misoprostol increases the risk PPH, vomiting and fever⁵⁴ Side effects can include vomiting, abdominal pain, diarrhoea, shivering and pyrexia⁷⁹
Recommendation	 Use only if no other injectable uterotonic is available (e.g. due to unexpected birth in low resource setting, storage conditions inadequate)^{10,78,80} If in a low resource setting with limited PPH treatment capability, consider use if: Injectable uterotonic has been administered AND Continued bleeding is anticipated and/or blood loss is estimated to be greater than or equal to 350 mL^{10,81} Misoprostol 600 micrograms orally or sublingual once immediately after birth^{10,78,80} Not recommended for CS birth⁷¹

5 Fourth stage

This guideline defines fourth stage as the first six hours immediately following the birth.

Table 13. Fourt	n stage management
-----------------	--------------------

Aspects	Risk reduction measures	
Routine care	 Frequent assessment is required, a Be alert for signs of haemodynam Prioritise placental inspection If incomplete or in doubt, monito Facilitate repair of tears or episioto Refer to Queensland Clinical Gu Monitor women, including for uterin Refer to Queensland Clinical Gu Actively encourage/assist women t Promote endogenous release of ox Keeping the woman warm and c Assisting with early breastfeedin Facilitating skin-to-skin contact v 	mic instability r woman and consult obstetrician mies requiring suturing udeline: <u>Perineal care⁸²</u> ne tone, every 15–30 minutes udelines: <u>Normal birth⁵³</u> to void soon after birth kytocin by: calm post birth ng (if preferred feeding method) with baby rning tool (e.g. Q-MEWT) to aid early
PPH risk factors	 Closely monitor every 15 minute 	/lactic oxytocin infusion depending on oxytocin causing receptor emodynamic effects ^{67,79}
Observations for women with PPH risk factors	Observation • Total Q-MEWT score • Respiratory rate • Oxygen saturation • Blood pressure • Heart rate • Temperature • Behaviour and consciousness • Fundus	 existing as clinically indicated Frequency Every 15–30 minutes for the first hour Every 30 minutes for the second hour Every 15–30 minutes Every 15–30 minutes Every 15–30 minutes Be alert to a slow steady trickle Visualise labia/perineum
	 Pain Urine output Oral intake Ongoing observations 	 Initial assessment then as clinically indicated Within the first two hours Use clinical judgement about commencement and consider individual circumstances After first 2 hours, continue as clinically indicated After CS or surgical treatment: incorporate into routine postoperative observation

6 Recognition of PPH

Blood loss can occur rapidly around the time of birth, with or without haemodynamic compromise. As soon as PPH recognised, call for assistance including the immediate attendance of an experienced/senior obstetrician.

6.1 Assessment of blood loss

Table 14. Assessment of blood loss

Aspect	Consideration	
Visual estimation	 Visual estimation of blood loss is subjective, can be imprecise and often leads to⁸⁴⁻⁸⁶: Underestimation of large volumes Overestimation of small volumes When conducting visual assessment of blood loss, consider: Volume Nature and speed¹⁷ Simulated scenarios and pictorial guides may improve staff accuracy^{86,87} 	
Quantitative measurement	 Measure blood loss or weigh blood-soaked items (e.g. linen, pads, swabs, drapes) to quantify volume⁴⁴ If weighing, 1 gram is equivalent to 1 mL blood loss⁸⁴ Provides a more accurate assessment of blood loss when compared with visual estimation^{86,87} Recommend measure/weigh blood loss if visual assessment exceeds 300 mL⁸⁵ 	

6.2 Haemodynamic compromise

Signs of haemodynamic compromise are a late indicator of PPH and may not be evident until large volumes of blood are lost (e.g. up to 25% of total blood volume or greater than 1500 mL).^{2,3,16}

Refer to Table 15. Clinical signs and symptoms of blood loss as a guide—many women will present without these direct correlations.⁸⁸ Conversely, compromise may occur earlier in women with^{41,89}:

- Gestational hypertension with proteinuria
- Anaemia
- Dehydration
- Small stature
- Cardiac disease

Table 15. Clinical signs and symptoms of blood loss

Blood loss (mL)	Systolic blood pressure	Signs and symptoms	Degree of shock
500–1000	Normal	Palpitations, dizziness, tachycardia	Compensated
1000–1500	Slight decrease	Weakness, sweating, tachycardia	Mild
1500–2000	Marked decrease (70–80 mmHg)	Restlessness, pallor, oliguria	Moderate
2000–3000	Profound decrease (50–70 mmHg)	Collapse, air hunger, anuria	Severe

Source: Adapted from Bonnar, J. Bailliere's Clinical Obstetrics and Gynaecology Vol. 14, No. 1, pp 1–18, 2000

7 Responding to PPH

7.1 Resuscitation

Initial response to PPH requires a multidisciplinary team approach^{3,16} to restore the woman's haemodynamic state whilst *simultaneously* identifying and treating the cause of bleeding.¹

Aspect	Consideration
DRS ABC	 Follow standard procedures for emergency resuscitation
	Danger, Response, Send for help, Airway, Breathing, Circulation
Initial assessment	• Assess volume and rate of bleeding—caution with underestimation ¹³
	• Lie woman flat ¹³
	Temperature every 15 minutes—prevent hypothermia ^{13,16}
	 High flow oxygen, 10–15 L/minute, via face mask regardless of maternal oxygen concentration^{16,88}
	 Monitor haemodynamic stability:
	 Heart rate and pulse oximetry continuously (if able)
	 Blood pressure every 5 minutes (more frequently if indicated)
	Tone: fundus atonic
	• Trauma: lacerations, uterine rupture or inversion, adequate blood clotting
	• Tissue: retained placental tissue and/or membranes. Fundus atonic and
Identify cause	unresponsive to uterotonics
(Four Ts)	Thrombin: fundus contracted (may become atonic), blood not clotting
	Unknown: assess for concealed bleeding (e.g. vault haematoma) and
	non-genital causes (e.g. subcapsular liver rupture)
	 Refer to Section 8 Management of Four Ts Establish IV access—ideally two IV cannulas (14–16 gauge)¹⁶
	 Establish IV access—Ideally two IV cannulas (14–16 gauge)¹⁰ One IV for fluid replacement, second IV for pharmacologic therapy
	 Some circumstances may require large volume central venous access
IV access	 If IV access unattainable, consider intraosseous access
	 Label blood samples as such, may not be suitable for all blood
	analysing equipment
	 Facilitate urgent collection and processing of^{13,16}:
	o FBC
	 Full chemistry profile (Chem20) [refer to Definitions]
	 Venous/arterial blood gas (ABG) (includes calcium and lactate) Coagulation profile (PT, INR, aPTT, fibrinogen)
Blood tests	 Blood cross match only required if:
	 No valid group and hold or cross-match available in laboratory
	 Woman has clinically significant antibodies
	 If point of care (PoC) blood clotting analyser available, request testing
	according to local guided strategy
	Use warm IV fluids during resuscitation wherever possible
	 Main aim is to promote tissue perfusion and oxygen carrying capacity
	 Avoid high-volume IV fluid replacement and dilutional coagulopathy^{90,91} Liss spratulation professional to colloid^{3,10}
	 Use crystalloid in preference to colloid^{3,10} Colloid use can be associated with dysfunction of clotting factors⁹⁰
	 Limit IV fluids to total 3.5 L¹⁶
Fluid replacement	 Crystalloid up to 2 L (1–2 mL every 1 mL of blood loss)²
	\circ If additional indicated, crystalloid or colloid up to 1.5 L can be infused ¹⁶
	 If colloid used, limit to 1.5 L¹⁶
	 If haemodynamic compromise or actively bleeding, consider RBC
	transfusion ¹⁶
	 Monitor fluid balance¹⁶ Aim for unions output of 20 ml /hour or more
	 Aim for urinary output of 30 mL/hour or more If actively blooding, transfuse early do not wait uppercessorily for
	 If actively bleeding, transfuse early do not wait unnecessarily for laboratory results^{16,47}
	\circ Clinical assessment is the main determinant ⁴⁴
Blood products	 Initially transfuse RBC two units (Group specific or O negative)
	 Use rapid infusion sets, pump sets or pressure bags, blood warmer
	 Consider MHP activation

7.2 Tranexamic acid

Give tranexamic acid (TXA) as soon as possible after onset of PPH⁹²—ideally within three hours^{1,2}

Tranexamic acid	Administration
Evidence summary	 Tranexamic acid in addition to uterotonics: Reduces postpartum blood loss, need for blood transfusion, and laparotomy to control bleeding Reduces death due to PPH (RR 0.81, 95% CI 0.65 to 1.00), especially if given within three hours of onset of PPH⁷⁹ (RR 0.69, 95% CI 0.52 to 0.91)⁹²
	 Does not increase risk of thromboembolic events
Intravenous (IV)	 Tranexamic acid 1 gram undiluted (100 mg/mL) IV over 10 minutes^{1,92} If bleeding persists after 30 minutes or stops and restarts within 24 hours of the first dose, a second dose of 1 gram may be administered^{10,92} Refer to Appendix D: Drugs and blood products for PPH treatment
Prescribing considerations	 Not recommended for routine prophylaxis following vaginal or CS birth^{16,93} Evidence does not demonstrate improved outcomes Restricted use in List of approved medicines (LAM)⁹⁴

7.3 Point of care blood clotting analysers

Table 18. Point of care blood clotting analysers

Aspect	Consideration
Context	 Relative real time testing to detect early changes in coagulation parameters^{95,96} Use may add value to treatment planning through⁹⁵⁻⁹⁸: More efficient diagnosis Distinguishing between surgical cause of bleeding or coagulopathy Diagnoses of specific type of coagulopathic impairment Directed blood replacement therapy Reduced over-transfusion of blood products Detection of hypercoagulability in various conditions, such as gestational diabetes, pre-eclampsia, and HELLP syndrome Subsequently, use of PoC testing may: Decrease blood loss Allow earlier termination of major haemorrhage protocol (MHP) Reduce the incidence of postpartum hysterectomy Reduce the length of inpatient stay Limitations⁹⁵: Cannot detect von Willebrand disease or other conditions that affect adherence to the endothelium Not recommended to test platelet function⁹⁹ Uncertainty regarding accuracy to detect fibrinolysis during early severe PPH (i.e. 800–1500 mL) and is not recommended to guide use of tranexamic acid¹⁰⁰
Devices	 Both thromboelastography (TEG[®]) and thromboelastometry (ROTEM[®]) PoC blood clotting analysers are used in Queensland Also referred to as viscoelastic haemostasis assay (VHA) and viscoelastic testing (VET)
Local facility considerations	 If a PoC blood clotting analyser is available: Follow a locally agreed algorithm relevant to the device used Provide education and training on use and interpretation of results Follow quality control activities as per manufacturer's instructions

7.4 Support during PPH

Aspect	Consideration
Communication	 Communicate sensitively and contemporaneously about the care being provided
	 As soon as possible, provide information to the woman and her support people regarding¹⁶:
	 The clinical circumstances of the PPH
	 The plan of management and treatment options
	 Address concerns raised by the woman and her support people
Pain management	Consider pain relief requirements during initial resuscitation and all
	subsequent treatments
Consent	 If treatment is likely to affect woman's fertility, prioritise gaining informed
	consent

8 Management of Four Ts

8.1 Tone

The incidence of PPH caused by uterine atony is rising.⁷⁹ The uterine cavity must be empty of tissue for effective uterine contraction.

Initial clinical and mechanical measures include:

- Massage uterine fundus to stimulate contractions^{2,16}
- Assess the need for bimanual compression^{10,13} [refer to Appendix A: Uterine atonia interventions]
 - Consider early, can be a lifesaving measure
- Expel blood clots from uterus—fundal stimulation by repetitive massage or squeezing
- Check placenta and membranes are complete
- Insert indwelling catheter to maintain empty bladder¹⁶
- Timely administration of first line uterotonics if preventative uterotonics ineffective^{79,101}

If bleeding persists, consider mechanical or surgical options [refer to Section 9 Intractable bleeding]

8.1.1 First line pharmacological therapy for uterine atony

The following uterotonics are useful in treatment of PPH due to atonia.¹³ Drugs differ in effectiveness and side effects and should be chosen based on individual circumstances and in the absence of contraindications.^{13,101} Generally drugs are administered in the order presented below and may be used in combination.^{13,102} [refer to Appendix D: Drugs and blood products for PPH treatment].

Table 20.	Oxytocin
-----------	----------

Oxytocin	Administration
Intravenous (IV) bolus	 Oxytocin 5 International units IV over 1–2 minutes^{13,16} May repeat after five minutes, maximum dose 10 International units IV^{13,16}
Intravenous (IV) infusion	 Add oxytocin 30 International units to 500 mL of either sodium chloride 0.9% <i>or</i> compound sodium lactate (Hartmann's solution) Administer oxytocin 5–10 International units per hour via infusion pump⁴⁷ At this concentration equates to 83–167 mL per hour via infusion pump No consistent evidence to support a minimum infusion duration, most commonly 2–4 hours⁶³—use clinical judgement^{17,103}
Prescribing considerations	 Oxytocin is most common first line uterotonic for treatment of PPH⁷⁹ If IV access unavailable or delayed, oxytocin 10 International units IM can be administered^{2,47} If IOL with oxytocin, may use the same infusion preparation at an increased rate For women with unstable cardiovascular conditions (e.g. hypovolemia, shock, cardiac disease), infusion may be a safer alternative to bolus dose^{61,79} If carbetocin used for third stage management, consider a non-oxytocic uterotonic as first line therapy⁷¹

Table 21. Ergometrine

Ergometrine	Administration
Intramuscular (IM)/Intravenous (IV)	 Ergometrine 250–500 micrograms IM^{13,16} Ergometrine 250–500 micrograms IV over 1–2 minutes^{13,16} May repeat 5 minutely if necessary, to a maximum dose 1 mg¹³
Prescribing considerations	 If oxytocin unavailable or bleeding does not respond to oxytocin, consider use of ergometrine¹⁰ Contraindicated with retained placenta, severe hypertension, preeclampsia, eclampsia, severe/persistent sepsis, and severe renal, hepatic, vascular or cardiac disease^{79,104} Consider concomitant anti-emetic Due to side effects, use with caution in IV administration¹⁰⁴

Table 22. Misoprostol

Misoprostol	Administration
Sublingual or per rectum	 Misoprostol 800–1000 micrograms sublingual or per rectum^{13,43} Consider clinical circumstances when determining optimal route Rectal, longer absorption time with prolonged activity Sublingual, rapid onset of action with side effects more likely^{9,105} Repeat dose not recommended¹⁰²: Within two hours of previous dose If experiencing hyperpyrexia and shivering
Prescribing considerations	 Not approved as first line medication on List of approved medicines (LAM)⁷⁷ Consider misoprostol if^{2,10,102}: Alternative uterotonics unavailable or contraindicated (e.g. asthma, hypertension) Bleeding not effectively controlled with oxytocin Limited evidence for efficacy of misoprostol used in combination with oxytocin, compared with oxytocin alone¹⁰¹ Common adverse effects include fever, nausea and vomiting, shivering and diarrhoea^{101,102} Consider the slow onset of action when treating uterine atonia¹⁰²

8.1.2 Second line pharmacological therapy for uterine atony

Table 23.	15-methyl	prostaglandin	F2 alpha	(carboprost)
10010 20.	10 moury	prootagiariari	i z uipilu	(ourseproor)

Carboprost	Administration	
Intramuscular	 Carboprost 250 micrograms IM Repeat as required every 15–90 minutes (not less than 15 minute intervals)¹⁰⁶ Most women (73%) respond to a single dose¹⁰² Maximum up to 2 mg (8 doses)¹⁶ 	
Intramyometrial	 Carboprost 500 micrograms Intramyometrial use not recommend by manufacturer or Therapeutic Goods Administration (TGA) approved¹⁰⁶ Administration via this route is at prescribing clinician's discretion¹³ 	
Prescribing considerations	 Indicated if bleeding continues after use of first line medications^{10,79,103} Use should be guided by clinical context, absence of contraindications, and consideration of available mechanical and surgical treatment options Refer to Section 9 Intractable bleeding Prior to administration of carboprost, commence: Oxygen therapy (prostaglandins can cause bronchospasm, abnormal ventilation-perfusion ratio and hypoxemia)^{79,102} Monitoring of heart rate, oxygen saturation and blood pressure Concomitant use of oxytocin and prostaglandins can potentiate cardiovascular side effects² Be aware of common side effects: hypertension, hypotension, pulmonary oedema, diarrhoea, nausea, vomiting, flushing, pyrexia and myalgia^{79,102} 	

8.2 Trauma

8.2.1 Genital trauma

Table 24. Genital trauma

Aspect	Consideration
Condition stable	 Assess extent of trauma and facilitate repair as soon as possible⁴³ Position to maximise visibility, lighting and maternal comfort⁴³ Provide adequate pain relief If arterial bleeders, promptly clamp or apply pressure Repair may require surgical exploration or ligation¹⁴ Refer to Queensland Clinical Guideline: <i>Perineal care</i>⁸²
Condition compromised	 Treat shock [refer to Section 7.1 Resuscitation] Apply pressure on the wound Assess analgesia requirements Urgently transfer to operating theatre (OT) for repair under anaesthetic Check uterine cavity is empty and uterus is intact General anaesthetic usually more appropriate when hemodynamically unstable¹⁰⁷
Suboptimal wound visualisation	 Transfer to OT Maximise lighting and position in lithotomy Under anaesthetic: Apply retractors to optimise visualisation Utilise assistants
Anaesthetic/ analgesia ineffective	 Assess rate of bleeding and weigh options of: Local or regional anaesthetic top up Transfer to OT for repair under regional or general anaesthetic
Puerperal haematoma	 Suspect in presence of: Vaginal tears, episiotomy, instrumental delivery or vaginal trauma¹⁰⁸ Inability to identify the cause of PPH (4 Ts) May have no visible/obvious cause Act promptly to: Resuscitate as required [refer to Section 7.1 Resuscitation] Perform vaginal/rectal examination to determine site and extent Consider transfer to OT for clot evacuation, primary repair, embolisation procedures and/or balloon tamponade of blood vessels

8.2.2 Cervical trauma

Aspect	Consideration	
Risk factors	 Precipitous labour, assisted vaginal birth, cervical suture, previous cervical surgery, primiparous¹⁰⁹ May occur in absence of risk factors 	
Presentation	 Profuse haemorrhaging during and after third stage of labour or a continuous bright red trickle¹¹⁰ Diagnosis strengthened by exclusion of other causes of PPH 	
Assessment	 If indicated, urgently transfer to OT Undertake assessment and repair under anaesthetic Optimise assessment with positioning, lighting, retractors and assistants To inspect the cervix: Grasp the cervix with two sponge forceps Remove and reapply forceps one at a time moving in a clockwise direction around the cervix, keeping forceps 2–3 cm apart Inspect for tears after each repositioning Continue until the full 360° of the cervix has been inspected¹¹⁰ 	
Repair	 Requires experienced obstetrician Most cervical tears will require repair in OT Consider expectant management of small cervical tears (i.e. less than 2 cm) with minimal bleeding¹⁰⁹ Use sponge forceps on either side of the laceration to aid visualisation¹¹⁰ Cervical tears may extend into the lower uterine segment¹¹⁰ If extensions, consider performing a laparotomy¹⁰⁹ If bleeding continues, investigate further and consider surgical interventions [refer to Section 9.2 Surgical treatment of intractable bleeding] 	

8.2.3 Uterine rupture

Uterine rupture can occur spontaneously or be associated with previous uterine trauma. The severity of the haemorrhage depends upon the extent of the rupture and may be a life-threatening obstetric emergency.^{50,111}

Aspect	Consideration
Risk factors	 Previous uterine surgery/trauma or CS⁵⁰ Refer to Queensland Clinical Guideline: <u>Vaginal birth after caesarean</u> <u>(VBAC)⁵¹</u> Grand multiparity¹¹² Age above 35 years⁵⁰ Use of oxytocin infusion in labour^{49,50} Obstructed labour¹¹² Malpresentation or undiagnosed cephalopelvic disproportion¹¹³ Dystocia during second stage of labour Macrosomic fetus^{49,112} Abnormal placentation Uterine abnormalities (e.g. rudimentary horn) Epidural analgesia¹¹³
Presentation	 Signs of uterine rupture may include^{50,112-114}: Maternal: tachycardia and signs of shock, impaired consciousness, sudden shortness of breath, constant abdominal pain, possible shoulder tip pain, uterine/suprapubic tenderness, change in uterine shape, pathological Bandl's ring, incoordinate or cessation of contractions, frank haematuria, abnormal vaginal bleeding, abdominal palpation of fetal parts, absent presenting part Fetal: abnormal cardiotocograph (CTG), often prolonged, persistent fetal bradycardia (most consistent early indicator),¹¹³ loss of fetal station Be alert to presenting signs—uterine rupture may be challenging to diagnose given the presentation can overlap with other conditions¹¹¹ Postpartum presentation often associated with^{115,116}: Pain, abdominal distension and persistent vaginal bleeding or minimal lochia Signs of shock, hypotension, and tachycardia Haematuria may occur if rupture extends into the bladder
Treatment	 if suspected intrapartum act to rapidly deliver baby and placenta Initiate procedure for Category 1 CS Urgently transfer to OT Under anaesthetic: Expeditious laparotomy¹¹⁴ Identify rupture site and confirm diagnosis Repair rupture using double layer closure (particularly for women who may contemplate future vaginal births)¹¹³ and absorbable sutures Consider hysterectomy (with midline rather than transverse incision) if: Defect is large or difficult to close Haemodynamic stability is threatened

8.2.4 Uterine inversion

Requires immediate treatment due to possibility of life-threatening haemorrhage and shock.

Table 27.	Uterine	inversion
-----------	---------	-----------

Aspect	Consideration		
	Uterine structural anomalies ¹¹⁷ Oxytocin use		
	Uterine over distension Pre-eclampsia		
Risk factors	Invasive placentation Manual removal of the placenta		
RISK Idelois	Short umbilical cord/excessive Applying fundal pressure before		
	umbilical cord traction separation of placenta		
	Tocolysis ¹¹⁸ Prolonged labour		
	Severe lower abdominal pain		
	Hypovolaemic shock disproportionate to revealed blood loss ¹¹⁷		
Descentation	 Be alert to profound bradycardia and hypotension 		
Presentation	Sudden onset of PPH, secondary to inadequate uterine contraction		
	• Protrusion of uterus (bluish grey mass) through cervical or vaginal orifice		
	 Irregularly shaped or absent palpable fundus¹¹⁷ 		
	Perform bimanual examination to detect ^{117,118} :		
Diagnosia	 Depression at the uterine fundus 		
Diagnosis	 Prescence of a smooth round mass protruding from the cervix or 		
	vagina, either visible or felt on pelvic examination		
	Urgently replace the uterus into correct anatomical position		
	• If oxytocin infusing, cease as replacement requires relaxed uterus ¹¹⁷		
	• If placenta in situ, cease attempts to deliver and leave in place for manual		
	removal in OT ^{3,117}		
Management	• Drugs may relax the cervical ring to facilitate replacement ^{3,118}		
	 Glyceryl trinitrate (GTN) 400 micrograms spray 		
	 Terbutaline 250 micrograms subcutaneous or IV 		
	 Magnesium sulphate 4 g IV infusion over 5 minutes 		
	Treat neurogenic and/or hypovolaemic shock ¹¹⁷		
	• Perform promptly ^{117,118} :		
	 Grasp protruding fundus with palm of hand 		
	 Direct fingers toward posterior fornix and lift uterus into vagina 		
Manual reduction	 Push the uterine fundus along long axis of vagina toward the umbilicus 		
	Once reinverted, maintain bi-manual compression		
	Start uterotonic therapy to contract uterus and prevent re-occurrence ³		
	Refer to Appendix A: Uterine atonia interventions		
	Exclude uterine rupture		
	 Lie woman flat or head slightly down, or in lithotomy 		
	Commence manual reduction until fundus in vagina		
Hydrostatic	• Have assistants bring labia into firm apposition to create a vaginal seal,		
reduction	alternatively use a ventouse cup if available		
	Using IV tubing, infuse warm saline into vagina to create increased		
	intravaginal pressure ¹¹⁷		
	Uterus gradually returns to its correct position over 10–15 minutes		
	May require up to 5–6 L of warm saline ¹¹⁷		
	 If manual reduction and/or hydrostatic repositioning unsuccessful, or homodynamic instability, promptly transfer to OT¹¹⁷ 		
	hemodynamic instability, promptly transfer to OT ¹¹⁷		
	Under anaesthetic give tocolytic agent to relax uterus and cervix ¹¹⁸		
	 Apply gentle manual pressure to the uterine fundus and return it to the abdominal position 		
	abdominal position		
Surgical	• If a dense constriction ring occurs, may require laparotomy to allow		
Surgical intervention	vaginal and abdominal manipulation of fundus ¹¹⁷		
	 Place clamps on uterine round ligaments and apply upward traction Use deep traction suture to manipulate fundus and to maintain 		
	 Use deep traction suture to manipulate fundus and to maintain positioning once retracted 		
	positioning once retracted		
	 If placenta in situ, reposition uterus then manually remove to limit PPH Immediately start uteratoria therapy to provent response to provent response to the respons		
	Immediately start uterotonic therapy to prevent reoccurrence ¹¹⁸		
	Assess uterine tone and consider intrauterine balloon tamponade Monitor to detect to accurrence		
	Monitor to detect re-occurrence		

8.3 Tissue

Table 28.	Tissue
-----------	--------

Aspect	Consideration
Trailing membranes	 Use sponge forceps to clamp membranes extending beyond introitus¹¹⁹ Without traction, roll forceps to create a rope of membranes¹¹⁹ Move forceps in an up and down motion and apply gentle traction Maternal pushing may assist in removal Once trailing membranes are delivered: Perform vaginal examination (VE) If additional membranes present, attempt delivery with fingers or forceps If large amount of membranes retained—transfer to OT for manual removal Observe uterine tone and blood loss—be alert to a slow steady trickle
Retained placenta	 Encourage maternal pushing and upright positions that promote gravity to assist delivery Confirm prophylactic third stage uterotonic has been given Insert in/out urinary catheter or indwelling catheter Reattempt controlled cord traction (CCT) and consider additional oxytocin (10 International units IV or IM)^{2,80} Check if risk factors for abnormal placentation If available, portable ultrasound may assist uterine cavity exploration^{3,120} If placenta appears trapped, perform a vaginal examination to firmly grasp and bring through cervix and introitus¹²⁰ Post delivery of placenta, massage fundus to promote sustained uterine tone^{119,120} If placenta unable to be delivered after above steps, transfer to OT for manual removal^{2,120}: Consider oxytocin infusion if placenta retained and excessive bleeding⁴³ Consider bimanual compression while awaiting and during transfer^{43,121,122}
Manual removal under anaesthesia	 Consider ultrasound guidance during procedure¹⁴ Provide anaesthetic/analgesia for uterine exploration and manual removal of placenta⁴³ If manual removal unsuccessful, apply gentle curettage with a large blunt curette⁴⁴ Post procedure: Explore the uterine cavity to verify it is intact and empty Check for cervical, vaginal, and perineal trauma and repair as required Check haemostasis achieved Recommend uterotonic drugs to promote uterine contractions² Consider the need for intrauterine balloon tamponade^{3,119} Refer to Section 9.1 Mechanical treatment of intractable bleeding Recommend a single dose of antibiotics^{2,120} (ampicillin or first generation cephalosporin)⁸⁰
Unexpected placenta accreta	 If placenta does not separate after birth of the baby, placenta accreta spectrum disorder (PAS) may be present¹²³ Do not attempt to forcibly remove the placenta¹²³ Individualise care, no single standard treatment for PAS^{124,125}: Conservative approach—uterine preservation techniques (e.g. surgical resection) may be considered dependent on degree of invasion and pelvic hypervascularity^{123,124} Radical treatment—prompt hysterectomy may be necessary^{4,120,125} Refer to Section 9.2 Surgical treatment of intractable bleeding
Not recommended	 Use of controlled cord traction (CCT) in the absence of uterotonic drugs or prior to signs of placental separation² Ergometrine—as tetanic contractions may delay placental expulsion^{43,80} Prostaglandin E2 alpha (dinoprostone)^{43,80} Oxytocin IV infusion to assist the birth of the placenta^{2,43} Use of umbilical vein for oxytocin injection^{43,120} and/or misoprostol⁸⁰

8.4 Thrombin

Coagulopathy risk assessment should include consideration of obstetric conditions and aetiology of PPH, not just estimation of blood loss.^{91,99} If coagulopathy is suspected, consult with a haematologist or transfusion specialist for advice on blood component replacement, laboratory monitoring and result interpretation.⁴¹

8.4.1 Coagulopathy principles

Remain cognisant that coagulopathy can occur at any stage of a PPH, and often co-occurs with other causes. 1,10

Table 29.	Coagulopathy	principles
-----------	--------------	------------

Aspect	Consideration
Clinical presentation	 Physiological, biochemical and metabolic derangement¹ Refer to Table 31. Laboratory values Be alert to differing presentations of coagulopathy of PPH and use clinical judgement to treat accordingly^{99,126}: Dilutional coagulopathy associated with significant blood loss, massive transfusion of blood products and high-level IV fluid replacement Localised consumption (e.g. placenta abruption) Generalised systemic coagulation failure with widespread clotting abnormalities (e.g. amniotic fluid embolism) Acute obstetric coagulopathy characterised by severe hyperfibrinolysis and dysfibrinogenemia Diverse causes of bleeding and can present in various situations¹²⁷
Communication with laboratory	 Inform if PoC blood clotting analyser (ROTEM[®]/TEG[®]) is being used Notify of impending arrival of urgent blood samples¹⁶ Communicate clearly the need for <i>emergency</i> provision of blood and blood components¹⁶ Identify minimum time till blood product availability, include transport time
Laboratory monitoring	 Baseline collection and processing of^{1,17}: FBC Blood group cross match Full chemistry profile (Chem20) [refer to Definitions] Venous/arterial blood gas (includes calcium and lactate) Coagulation profile (PT, INR, aPTT, fibrinogen) Monitor FBC, coagulation profile, calcium and ABG every 30–60 minutes depending on severity of the bleeding, or until bleeding stops, and at least every 4 units of RBC^{1,128} Repeated testing, comparison of results and reassessment are vital to management¹²⁸ If PoC blood clotting analyser (ROTEM[®]/TEG[®]) available, follow local algorithm for targeted replacement Refer to Table 31. Laboratory values
Avoid hypothermia and acidosis	 Optimise body temperature¹ (i.e. more than 35 °C) Use fluid warmers and forced air warmers Minimise exposure, remove wet linen, provide warm blankets Monitor temperature at least every 15 minutes Maintain oxygenation, cardiac output, tissue perfusion Monitor arterial blood gases (pH, lactate, base excess) Mortality is increased when hypothermia and acidosis occur with coagulopathy (the 'lethal triad')²
Hypocalcaemia	 Monitor and correct calcium levels^{2,129} Provide calcium supplementation at least every 4 units of RBC, or if ionised calcium less than 1 mmol/L¹³⁰ Citrate from transfused blood often causes hypocalcaemia¹²⁹ Recommend 10% calcium gluconate 10 mL IV ¹³⁰
Disseminated intravascular coagulation (DIC)	 Be alert to early DIC characterised by falling platelets and fibrinogen levels and rising fibrin degradation products⁹⁹ Associated with placental abruption, amniotic fluid embolism, severe pre-eclampsia or HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome; acute fatty liver of pregnancy; fetal death in utero; septicaemia, dilutional coagulopathy

8.4.2 Correction of coagulopathy

Table 30.	Correction	of coagulopath	y
-----------	------------	----------------	---

Aspect	Consideration
Context	 Give RBC in response to haemodynamic changes and estimated blood loss rather than Hb trigger—do not wait for blood results to treat^{17,41,99}: Oozing from puncture/cannulation/injection sites or surgical field Haematuria Petechial, subconjunctival, and mucosal haemorrhage Blood that no longer clots Uterine atonia secondary to increased fibrin degradation products Temperature less than 35 °C
Blood product replacement	 If PoC blood clotting analyser (ROTEM®/TEG®) available, use PoC guided correction as per locally agreed algorithm^{2,91,99} Targeted blood and blood product replacement If PoC blood clotting analyser not available, transfuse blood components as per locally agreed ratio-based configuration¹ Be guided by laboratory findings No strong evidence for optimal blood product transfusion ratio^{1,3} Aim for red blood cell (RBC):fresh frozen plasma (FFP):platelet ratio of at least 2:1:1¹ Equates to at least 1 unit of FFP for every 2 units of RBC, and 1 adult dose of platelets (equivalent to 4 donor units) for every 8 units RBC¹ Promptly achieve ratio and maintain until bleeding controlled¹ FFP administered before haemostatic testing may be justified for placental abruption, amniotic fluid embolism or delayed PPH recognition⁹⁹ Evidence suggests early FFP transfusion (i.e. within first 60 minutes) not associated with adverse maternal outcomes when compared with no or late plasma transfusion¹³¹ During active PPH, if platelets less than 75 x 10⁹/L transfuse to maintain target of 50 x 10⁹/L^{103,126} Assess fibrinogen and replace as required¹ Blood products frequently issued from blood bank as 'packs' to avoid over provision, over transfusion or waste of blood products¹³²
Fibrinogen replacement	 Fibrinogen deficiency, not thrombin, is the main indicator of haemorrhage severity^{98,133} Fibrinogen is the first coagulation factor to decrease and may be low despite normal PT/aPTT^{98,99} Pregnancy is associated with hypercoagulability⁹⁵⁻⁹⁷ Fibrinogen in pregnancy 4–6 g/L, compared to 2–4 g/L non-pregnant¹³⁴ Fibrinogen level less than 2 g/L is a positive predictor for progression to severe PPH^{95,98,99,135} Monitor fibrinogen early and use timely replacement therapy² Request Clauss or clottable fibrinogen laboratory test More reliable than derived fibrinogen assays (e.g. prothrombin time)⁴¹ If PoC blood clotting analyser available, replace fibrinogen when:

8.4.3 Laboratory values

Measure the following parameters early and frequently. With successful treatment, values should trend toward normal.^{38,41,140}

Investigation (gestation)	Reference range	Units	Critical physiologic derangement
Hb (25–42 weeks)	98–137	g/L	less than 70
Platelets (> 25 weeks)	150–430	x 10 ⁹ /L	less than 50
APTT (Adult)	25–38	seconds	greater than 1.5 x normal
INR (Adult)	0.9–1.2	Result is a ratio	greater than 1.5 x normal
Prothrombin time (Adult)	9–13	seconds	
Fibrinogen (by term)	5–6	g/L	less than 2.0
Ionised calcium	1.15–1.32	mmol/L	less than 1
рН	Arterial 7.35–7.45 Venous 7.32–7.43		less than 7.2
Lactate	0.5 – 2.2	mmol/L	greater than 4
Base excess	greater than minus 6	mmol/L	less than minus 6

Table 31. Laboratory values

8.4.4 Cross matched RBC not available

Take blood for cross matching prior to giving O negative RBC—do not wait for results.¹⁶

Table 32. Blood cell replacement

Aspect	Consideration
No blood group and antibody	Send blood for urgent group and antibody testingRequest compatible blood
screen	 Transfuse O negative RBC (ideally Kell negative)⁴⁴
Blood group and antibody screen negative	 Laboratory onsite Transfuse ABO Rh compatible RBC Laboratory offsite Transfuse O negative RBC Await group specific RBC
Blood group and antibody screen positive	 Await antibody testing and cross match for provision of compatible blood While waiting and if urgent, in consultation with a haematologist, transfuse most suitable uncross matched RBC
Screened homologous blood unavailable in time frame	Transfuse O negative RBC emergency stockContact RSQ for urgent retrieval

9 Intractable bleeding

Uterine atony is a leading cause of intractable bleeding that does not respond to first line interventions, first and second line uterotonics, and requires mechanical or surgical interventions to control.^{102,141,142}

Initiate life-saving mechanical and/or surgical interventions early¹³:

- Selection of procedure is best determined based on cause of bleeding, clinical expertise, service capabilities and individual clinical circumstances¹³
- Treat coagulopathy concurrently [refer to Section 8.4.2 Correction of coagulopathy]

Table 33. Intractable bleeding

Aspect	Consideration	
Persistent bleeding	 Urgently identify the source and cause of bleeding¹ If uterus atonic, apply bimanual compression¹⁰² [refer to Appendix A: Uterine atonia interventions] Increase monitoring of observations guided by clinical judgement¹³ Initiate blood component replacement as soon as possible Review criteria for: MHP activation [refer to Section 10 Major haemorrhage] PoC blood clotting analysis (if available) 	
Transfer to operating theatre	 If urgent transfer to OT required Transfer woman flat with high-flow oxygen 	
In theatre preparation	 Provide warmth to facilitate clotting² Warm blood and IV fluids Warm OT environment and consider external warming device Apply pneumatic calf compression device to reduce risk of venous thromboembolism (VTE) Involve the most experienced staff (consider external consultations if necessary) including obstetrician and anaesthetist Where expertise available consider cell salvaging^{2,39} 	

9.1 Mechanical treatment of intractable bleeding

Table 34. Mechanical procedures

Aspect	Consideration	
Context	 Under anaesthetic check uterine cavity is empty and intact Confirm source of bleeding is uterine atony 	
Intrauterine tamponade balloon	 If bimanual compression has been effective, consider intrauterine balloon tamponade (e.g. Bakri®)^{13,16} [refer to Appendix A: Uterine atonia interventions] Provides an efficient treatment option for uterine atony^{17,102} After insertion, assess blood loss: If bleeding continues, balloon tamponade may be ineffective—review aetiology of PPH, check balloon placement¹⁰ and consider surgical interventions^{17,132} If bleeding ceases on insertion, monitor fundal height, uterine cramping and signs of increased blood loss regularly¹⁴³ Assess drainage port for cumulative blood loss regularly Increasing uterine size with no drainage from balloon may indicate blocked drain and/or bleeding within uterine cavity If bleeding suspected, assess woman's haemodynamic stability and consult obstetrician¹⁴³ Concurrently monitor coagulation, ideally with TEG[®] or ROTEM[®] If coagulopathy present, liaise early and closely with anaesthetic staff Commence broad spectrum antibiotics Continue or commence oxytocic infusion after insertion 	
Uterine packing	 Weak evidence suggests uterine packing not recommended for the management of uterine atony as can conceal bleeding⁸⁰—use clinical judgement 	

9.2 Surgical treatment of intractable bleeding

Table 35.	Surgical	procedures
10010-00.	ourgiour	procedures

Aspect	Consideration
Context	 If critically bleeding, treat the coagulopathy concurrently¹⁰ Timing is critical Weigh benefits of conservative versus aggressive management Assess if quicker and safer to do subtotal hysterectomy based on surgeon's skill and maternal condition Use hot packs intra-abdominally Closely monitor haemostasis after any surgical procedure and consider appropriate transfer to intensive or high dependency units^{16,17}
Haemostatic uterine suture (e.g. B-Lynch suture)	 Use to treat uterine atony¹³² Laparotomy¹³² or hysterotomy¹⁰ is required to place absorbable suture May be considered appropriate where active bleeding can be controlled while preparing for surgery¹⁷ May reduce the need for hysterectomy¹³² Refer to Appendix A: Uterine atonia interventions
Uterine or internal iliac artery embolisation	 If blood pressure stable, consider selective uterine or internal iliac artery embolisation^{10,44} Indicated for bleeding after vaginal or CS birth, or complications due to surgery⁴⁴ Requires interventional radiologist and necessary infrastructure⁴⁴ Highly effective, 87–95% success rate based on no need for hysterectomy or other invasive procedures^{10,44,102}
Utero-ovarian artery ligation	 Consider when compression or tamponade unsuccessful Use to temporarily slow blood flow to the uterus, not obliterate it⁴⁴ Fertility preserving surgical technique¹⁰ Can involve ligation of one or both uterine arteries, lower uterine arteries or one or both ovarian arteries¹⁶ with absorbable suture⁴⁴ Success rate of 42–88% for control of bleeding¹⁰ Refer to Appendix B: Surgical ligation procedures
Internal iliac artery ligation	 Consider in cases where rapid control of PPH is required¹⁰ and compression or tamponade unsuccessful Only consider if appropriate clinical expertise is available (e.g. oncogynaecologist, vascular surgeon)¹⁶ Consider if fertility preservation is important¹³² May be used as a preventative measure or after a hysterectomy with persistent bleeding^{10,132} Refer to Appendix B: Surgical ligation procedures
Hysterectomy	 May be necessary in cases of uterine rupture, abnormal placentation, or when other measures have ineffectively controlled bleeding¹³² Judiciously apply aortic compression (below the level of the renal arteries) as a temporising measure¹⁷ Perform early if life is threatened^{17,44} Decision to proceed should be made by an experienced consultant clinician and preferably discussed with a second experienced clinician^{2,16}

10 Major haemorrhage

Reduction of morbidity and mortality associated with critical bleeding can be achieved through¹:

- Early detection and a rapid, coordinated multidisciplinary approach to control the haemorrhage, correct coagulopathy and normalise physiological parameters
- Implementation of a major haemorrhage protocol (MHP) that is reviewed annually by local key stakeholders
- A structured approach that includes laboratory escalation procedures for timely delivery and administration of blood components
- For further considerations, refer to Table 36. MHP considerations

10.1 Major haemorrhage protocol considerations

Table 36. MHP considerations

Aspect	Consideration
Activation criteria	 Woman is actively bleeding with one or more of the following¹: Major obstetric haemorrhage (i.e. greater than 2500 mL)^{2,142} Actual or anticipated requirement of greater than or equal to 5 units of RBC in four hours Haemodynamic instability Clinical or laboratory evidence of coagulopathy In low resource settings as per locally developed protocol
Roles and communication	 Senior clinician¹: Identifies need and activates MHP Contact specialist staff according to local setting (e.g. laboratory/blood bank, anaesthetist, haematologist, surgeon, interventional radiologist). Contact RSQ early for transfer advice as required Laboratory staff¹: Prepares (i.e. thaws) and issues blood components Provides group specific blood components as soon as possible Anticipates additional blood component requirements Considers staff resources Liaises with haematologist Haematologist: Consults on blood component and other therapies Assists with result interpretation
Co-ordination of blood component and other therapies	 Recommend early use of Tranexamic acid¹ Refer to Section 7.2 Tranexamic acid Pre-designate: Dose, timing and ratio of blood component therapy Triggers for administration of fibrinogen replacement therapy and calcium gluconate Refer to Section 8.4 Thrombin
Laboratory testing	 Pre-designate: Baseline blood tests for collection on activation of MHP Refer to Table 29. Coagulopathy principles Critical targets for results Refer to Table 31. Laboratory values
PoC blood clotting analyser algorithm	 If PoC blood clotting analyser (e.g. ROTEM®/TEG®) being utilised, agree on an algorithm relevant to local conditions that aids: Correct specimen collection Interpretation of results Blood and blood product replacement therapy triggers Retesting requirements Identification of the location of the PoC blood clotting analyser When to access expert advice Refer to Section 7.3 Point of care blood clotting analysers
PoC testing obstetric specific reference ranges	 Significant variation in reference ranges exist between the pregnant and non-pregnant population^{144,145} Inclusion of obstetric specific reference ranges can optimise management of major obstetric haemorrhage^{97,134,145} ROTEM[®] Gestational diabetes and body mass index do not change hypercoagulability of pregnancy^{146,147} TEG[®] No widely accepted and utilised TEG[®] reference ranges for pregnancy^{95,148} Refer to Appendix E: PoC testing obstetric specific reference ranges
Deactivation	 If bleeding controlled, senior clinician contacts laboratory/blood bank staff to deactivate MHP¹ Continue with targeted optimisation of coagulation, ongoing assessment and correction of physiological and biochemical parameters Return unused blood products to laboratory/blood bank

11 Women who cannot receive a blood transfusion

Blood transfusion may not be a management option in some situations. This may be due to personal choice, religious and/or cultural beliefs, the presence of rare blood groups or complex antibodies, or the unavailability of blood products.^{41,149}

Aspects	Risk reduction measures
Jehovah Witnesses	 Women vary in their choice, therefore establish individual preferences¹⁴⁹ Generally, will not accept: Whole blood or any of its four major components (RBC, platelets, white blood cells and plasma)¹⁵⁰ Use of any blood sample for blood cross-matching¹⁵¹ Autologous blood transfusion, but some women may accept blood in a continuous loop (e.g. cardiopulmonary bypass, haemodialysis, intraoperative cell salvage)¹⁵⁰ Generally, will accept: Recombinant products such as erythropoiesis stimulating agents and granulocyte colony-stimulating factors Pro-thrombotic drugs such as tranexamic acid Intravenous iron¹⁴⁹ Some accept blood fractions/derivatives (e.g. albumin solutions, coagulation factors, globulins, fibrinogen concentrate)
Plan care	 Document woman's preferences clearly, ideally during the antenatal period³⁹ Clarify what constitutes unacceptable treatment in relation to blood products and fluid resuscitation management^{39,149} Recommend and discuss ⁴¹: Planned location of birth Optimisation of antenatal haemoglobin Early treatment for any degree of anaemia¹⁵⁰ Identification of placental site Active management of third stage of labour Risk of uterine atonia associated with longer duration of active labour, oxytocin in labour and operative/assisted birth^{24,33,152} Risks and benefits of potential management options Advance Health Directive¹⁵¹ and place a certified copy in the medical record Refer to Table 6. Antenatal risk management Refer to Section 4.1 Third stage If blood products declined, follow local documentation protocols (e.g. specific consent forms, stickers, or chart notations)
Intrapartum	 At the onset of labour, recommend review by a consultant obstetrician and anaesthetist, and consult with haematologist as required¹⁴⁹ Consider the need for pharmacological, mechanical and surgical procedures to control bleeding early^{39,150} Hysterectomy is the definitive procedure to minimise life-threatening haemorrhage when transfusion is not an option⁴¹ If CS required and/or high risk of PPH, consider (as is available at local facility): Interventional radiology Reinfusion drains Intraoperative cell salvage (if skilled team available and acceptable as a treatment)^{39,41,150} particularly if blood loss is anticipated to be significant

12 Postnatal care after PPH

Table 38. Postnatal care

Aspects	Consideration		
Inter-hospital transfer	Transfer early, contact RSQ on 1300 799 127		
Haemodynamic state	 Transfer to high dependency/intensive care unit for observation¹⁶ If condition not critical Observe in birth suite for two hours, transfer to postnatal unit if stable First 24 hours post birth, monitor vital signs, uterine tone and blood loss at least four hourly, monitor fluid balance After 24 hours post birth, monitor as per clinical condition 		
Haemoglobin	 Take six hours after stabilisation and repeat within 24 hours of birth Offer treatment for postpartum anaemia—contributes to fatigue, postpartum depression, poor infant bonding and poor lactation⁴⁴ If Hb less than 70 g/L and/or symptomatic offer RBC transfusion^{2,41} If RBC transfusion declined offer parenteral iron therapy If Hb less than 70 g/L and asymptomatic, offer parenteral iron therapy If Hb is between 70–90 g/L, asymptomatic and no continued threat of bleeding, offer parenteral iron therapy or oral therapy with vitamin C supplement on an individual basis^{39,41} Provide information on ways to increase dietary iron 		
VTE	 Consider mechanical and pharmacological VTE prophylaxis as increased risk following PPH^{2,17} Encourage early mobilisation and avoid dehydration Refer to Queensland Clinical Guideline: <u>Venous thromboembolism (VTE)</u> prophylaxis in pregnancy and the puerperium¹⁵³ Observe for VTE 		
Mother-infant interaction	 Support maternal and infant bonding Facilitate regular skin-to-skin contact with supervision Support infant feeding and offer lactation support as required If unable to lactate or persistent hypotension, consider Sheehan's syndrome Discuss risks of co-sleeping and bed sharing due to anaemia related fatigue [refer to Queensland Clinical Guideline: <u>Safer infant sleep</u>¹⁵⁴] 		
Debriefing	 Offer the woman and family debriefing/clinical disclosure by senior team member(s), preferably by clinicians who were at the event^{16,155} Offer additional opportunities for discussion/debrief six weeks postpartum Offer information about possible psychological and psychosocial responses following PPH (e.g. flashbacks, anxiety, depression, post-traumatic stress, relationship stress) and provide support resources¹⁵⁵ Offer social worker review 		
Preparation for discharge	 Advise anticipate a longer physical recovery and possible issues with initiation and maintenance of exclusive breastfeeding^{155,156} Particularly if severe or major haemorrhage, or a blood transfusion Communicate a comprehensive discharge summary to other health care providers 		

References

1. National Blood Authority (NBA). Patient blood management guideline for adults with critical bleeding [Internet]. 2023 [cited 2024 January 29]. Available from: <u>https://www.blood.gov.au/clinical-guidance/patient-blood-management</u>.

2. Muñoz M, Stensballe J, Ducloy-Bouthors AS, Bonnet MP, De Robertis E, Fornet I, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus 2019;17(2):112-36. doi:10.2450/2019.0245-18.

3. Bienstock JL, Eke AC, Hueppchen NA. Postpartum hemorrhage. N Engl J Med 2021;384(17):1635-45. doi:10.1056/NEJMra1513247.

The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Placenta accreta spectrum (PAS) C-Obs 20. [Internet]. 2023. [cited 2024 March 28]. Available from: <u>https://ranzcog.edu.au</u>.
 Australian College of Midwives. Aims and scope [Internet]. 2024 [cited 2024 March 03]. Available from: <u>https://www.womenandbirth.org</u>.

 Australian Government Department of Health and Aged Care. First evaluation report: national stillbirth action and implementation plan. [Internet]. 2023 [cited 2024 March 4]. Available from: <u>https://www.health.gov.au</u>.
 Australian Institute of Health and Welfare. National maternity data development project: primary postpartum haemorrhage: research brief no.8. Cat. no. PER 82 [Internet]. 2016 [cited 2024 January 31]. Available from: <u>http://www.aihw.gov.au</u>.

8. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A, Biesty LM. Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews. [Internet]. 2019, [cited 2024 January 31]. Issue 2. Art No.: CD007412. DOI:10.1002/14651858.CD007412.pub5.

9. World Health Organization. WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. 2018. [cited 2024 January 29]. Available from: <u>https://who.int</u>.

10. Escobar MF, Nassar AH, Theron G, Barnea ER, Nicholson W, Ramasauskaite D, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet 2022;157(1):3-50. doi:10.1002/ijgo.14116.

11. van Stralen G, von Schmidt Auf Altenstadt JF, Bloemenkamp KW, van Roosmalen J, Hukkelhoven CW. Increasing incidence of postpartum hemorrhage: the Dutch piece of the puzzle. Acta Obstet Gynecol Scand 2016;95(10):1104-10. doi:10.1111/aogs.12950.

12. Australian Institute of Health and Welfare. Australia's mothers and babies. Data tables: national maternal mortality data collection annual update 2021 [Internet]. 2023 [cited 2024 January 31]. Available from: https://www.aihw.gov.au.

The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Management of postpartum haemorrhage. [Internet]. 2021. [cited 2024 January 31]. Available from: <u>https://ranzcog.edu.au</u>.
 American College of Obstetricians and Gynecologists (ACOG). Postpartum hemorrhage: Practice bulletin No 183. Obstetrics and Gynecology 2017;130(4):168-86.

15. World Health Organization. International statistical classification of diseases and related health problems (ICD) 11th revision. 2022. [cited 2024 January 31]. Available from: <u>https://who.int</u>.

16. Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum

haemorrhage. Guideline No. 52. [Internet]. 2016. [cited 2024 February 05]. Available from: <u>https://rcog.org.uk</u>. 17. Sentilhes L, Merlot B, Madar H, Sztark F, Brun S, Deneux-Tharaux C. Postpartum haemorrhage: prevention and treatment. Expert Rev Hematol 2016;9(11):1043-61. doi:10.1080/17474086.2016.1245135.

18. Lutgendorf MA, Ennen CS, McGlynn A, Spalding CN, Deering S, Delorey DR, et al. Interprofessional obstetric simulation training improves postpartum haemorrhage management and decreases maternal morbidity: a before-and-after study. BJOG 2024;131(3):353-61. doi:10.1111/1471-0528.17640.

19. Buhlmann M, Ewens B, Rashidi A. The impact of critical incidents on nurses and midwives: A systematic review. Journal of Clinical Nursing 2021;30(9-10):1195-205. doi:10.1111/jocn.15608.

20. Arriaga AF, Szyld D, Pian-Smith MCM. Real-time debriefing after critical events: exploring the gap between principle and reality. Anesthesiology Clinics 2020;38(4):801-20. doi:10.1016/j.anclin.2020.08.003.

21. Queensland Clinical Guidelines. Standard care. Guideline No. MN22.50-V2-R27. [Internet]. Queensland Health. 2022. [cited 2024 March 11]. Available from: <u>https://www.health.gld.gov.au/qcg</u>.

22. Patek K, Friedman P. Postpartum hemorrhage-epidemiology, risk factors, and causes. Clin Obstet Gynecol 2023;66(2):344-56. doi:10.1097/GRF.000000000000782.

23. Thams AB, Larsen MH, Rasmussen SC, Jeppegaard M, Krebs L. Incidence of postpartum hemorrhage and risk factors for recurrence in the subsequent pregnancy. Arch Gynecol Obstet 2023;307(4):1217-24. doi:10.1007/s00404-022-06591-4.

24. Nyflot LT, Sandven I, Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M, et al. Risk factors for severe postpartum hemorrhage: a case-control study. BMC Pregnancy Childbirth 2017;17(1):17. doi:10.1186/s12884-016-1217-0.

25. Fyfe EM, Thompson JM, Anderson NH, Groom KM, McCowan LM. Maternal obesity and postpartum haemorrhage after vaginal and caesarean delivery among nulliparous women at term: a retrospective cohort study. BMC Pregnancy Childbirth 2012;12:112. doi:10.1186/1471-2393-12-112.

26. Corbetta-Rastelli CM, Friedman AM, Sobhani NC, Arditi B, Goffman D, Wen T. Postpartum hemorrhage trends and outcomes in the United States, 2000-2019. Obstetrics and Gynecology 2023;141(1):152-61. doi:10.1097/AOG.000000000004972.

27. Oberg AS, Hernandez-Diaz S, Palmsten K, Almqvist C, Bateman BT. Patterns of recurrence of postpartum hemorrhage in a large population-based cohort. Am J Obstet Gynecol 2014;210(3):229 e1-8. doi:10.1016/j.ajog.2013.10.872.

28. Feduniw S, Warzecha D, Szymusik I, Wielgos M. Epidemiology, prevention and management of early postpartum hemorrhage - a systematic review. Ginekologia Polska 2020;91(1):38-44. doi:10.5603/GP.2020.0009.

29. Mansukhani R, Shakur-Still H, Chaudhri R, Bello F, Muganyizi P, Kayani A, et al. Maternal anaemia and the risk of postpartum haemorrhage: a cohort analysis of data from the WOMAN-2 trial. Lancet Glob Health 2023;11(8):e1249-e59. doi:10.1016/S2214-109X(23)00245-0.

30. Miller EMS, Sakowicz A, Leger E, Lange E, Yee LM. Association between receipt of intrapartum magnesium sulfate and postpartum hemorrhage. AJP Rep 2021;11(1):e21-e5. doi:10.1055/s-0040-1721671.

31. Skalkidou A, Sundstrom-Poromaa I, Wikman A, Hesselman S, Wikstrom AK, Elenis E. SSRI use during pregnancy and risk for postpartum haemorrhage: a national register-based cohort study in Sweden. BJOG 2020;127(11):1366-73. doi:10.1111/1471-0528.16210.

32. Hews-Girard JC, Galica J, Goldie C, James P, Tranmer JE. Identifying the effect of inherited bleeding disorders on the development of postpartum hemorrhage: a population-based, retrospective cohort study. Res Pract Thromb Haemost 2023;7(2):e100104. doi:10.1016/j.rpth.2023.100104.

33. Bernitz S, Betran AP, Gunnes N, Zhang J, Blix E, Oian P, et al. Association of oxytocin augmentation and duration of labour with postpartum haemorrhage: A cohort study of nulliparous women. Midwifery 2023;123:103705. doi:10.1016/j.midw.2023.103705.

34. Bais JM, Eskes M, Pel M, Bonsel GJ, Bleker OP. Postpartum haemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard (> or = 500 ml) and severe (> or = 1000 ml) postpartum haemorrhage. European Journal of Obstetrics & Gynecology and Reproductive Biology 2004;115(2):166-72. doi:10.1016/j.ejogrb.2003.12.008.

35. Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013;209(5):449 e1-7. doi:10.1016/j.ajog.2013.07.007.

36. Sheiner E, Levy A, Mazor M. Precipitate labor: higher rates of maternal complications. European Journal of Obstetrics & Gynecology and Reproductive Biology 2004;116(1):43-7.

doi:<u>https://doi.org/10.1016/j.ejogrb.2004.02.006</u>.

37. Collaboration ALE. Australian pregnancy care guidelines [Internet]. 2023 [cited 2024 March 7]. Available from: <u>https://leappguidelines.org</u>.

38. Queensland Health. Pathology Queensland haematology and coagulation reference ranges [Internet]. 2022 [cited 2024 February 26]. Available from: <u>http://www.health.qld.gov.au</u>.

39. Royal College of Obstetricians and Gynaecologists. Blood transfusions in obstetrics. Guideline No. 47. [Internet]. 2015. [cited 2024 March 7]. Available from: https://rcog.org.uk.

40. Australian Red Cross Lifeblood. Iron optimisation in maternity: A guide for health professionals involved in antenatal care [Internet]. 2022 [cited 2024 March 20]. Available from: https://lifeblood.com.au.

41. National Blood Authority (NBA). Patient blood management guidelines: module 5 obstetrics and maternity. Canberra Australia: NBA; 2015 [cited 2024 February 26]. Available from: <u>https://blood.gov.au</u>.

42. Stewart MJ, Richmond D, Mooney S, Esler S, Churilov L, Israelsohn N, et al. Diagnostic utility of MRI features of placental adhesion disorder for abnormal placentation and massive postpartum hemorrhage. AJR Am J Roentgenol 2021;217(2):378-88. doi:10.2214/AJR.19.22661.

43. National Institute for Health and Clinical Excellence (NICE). Intrapartum care. Clinical Guideline 235. 2023. [Internet]. [cited 2024 January 29]. Available from: <u>https://www.nice.org.uk</u>.

44. Robinson d, Basso M, Chan C, Duckitt K, Lett R. Guideline No. 431: postpartum hemorrhage and hemorrhagic shock. J Obstet Gynaecol Can 2022;44(12):1293-310.e1. doi:10.1016/j.jogc.2022.10.002.
45. Davey MA, Flood M, Pollock W, Cullinane F, McDonald S. Risk factors for severe postpartum haemorrhage: A population-based retrospective cohort study. Aust N Z J Obstet Gynaecol 2020;60(4):522-32. doi:10.1111/ajo.13099.

46. Bruggemann C, Carlhall S, Grundstrom H, Ramo Isgren A, Blomberg M. Cumulative oxytocin dose in spontaneous labour - Adverse postpartum outcomes, childbirth experience, and breastfeeding. European Journal of Obstetrics & Gynecology and Reproductive Biology 2024;295:98-103. doi:10.1016/j.ejogrb.2024.01.040.

47. Sentilhes L, Vayssiere C, Deneux-Tharaux C, Aya A, Bayoumeu F, Bonnet M, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF) in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). European Journal of Obstetrics & Gynecology and Reproductive Biology 2016;198:12-21.

48. Webster J, Larsen E, Booker C, Laws J, Marsh N. Prophylactic insertion of large bore peripheral intravenous catheters in maternity patients for postpartum haemorrhage: A cohort study. Aust N Z J Obstet Gynaecol 2018;58(5):548-52. doi:10.1111/ajo.12759.

Dimitrova D, Kastner AL, Kastner AN, Paping A, Henrich W, Braun T. Risk factors and outcomes associated with type of uterine rupture. Arch Gynecol Obstet 2022;306(6):1967-77. doi:10.1007/s00404-022-06452-0.
 Overtoom EM, Huynh TN, Rosman AN, Zwart JJ, Schaap TP, Vogelvang TE, et al. Predicting the risks and recognizing the signs: A two-year prospective population-based study on pregnant women with uterine rupture in the Netherlands. J Matern Fetal Neonatal Med 2024;37(1):2311083. doi:10.1080/14767058.2024.2311083.
 Queensland Clinical Guidelines. Vaginal birth after caesarean (VBAC). Guideline No. MN20.12-V5-R25. [Internet]. Queensland Health. 2020. [cited 2024 March 27]. Available from: https://www.health.qld.gov.au/qcg.
 Queensland Clinical Guidelines. Induction of labour. Guideline No. MN22.22-V9-R27. [Internet]. Queensland Health. 2022. [cited 2024 March 19]. Available from: https://www.health.gld.gov.au/qcg.

53. Queensland Clinical Guidelines. Normal birth. Guideline No. MN22.25-V5-R27. [Internet]. Queensland Health. 2022. [cited 2024 March 13]. Available from: <u>https://www.health.qld.gov.au/qcg</u>.

54. Gallos ID, Papadopoulou A, Man R, Athanasopoulos N, Tobias A, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews. [Internet]. 2018, [cited 2024 February 15]. Issue 12. Art No.: CD011689. DOI:10.1002/14/651858 CD01469. pub2

DOI:10.1002/14651858.CD011689.pub3.

55. Chaudhary P, Priyadarshi M, Singh P, Chaurasia S, Chaturvedi J, Basu S. Effects of delayed cord clamping at different time intervals in late preterm and term neonates: a randomized controlled trial. European Journal of Pediatrics 2023;182(8):3701-11. doi:10.1007/s00431-023-05053-6.

56. Hofmeyr GJ, Mshweshwe NT, Gulmezoglu AM. Controlled cord traction for the third stage of labour. Cochrane Database of Systematic Reviews. [Internet]. 2015, [cited 2024 February 15]. Issue 1. Art No.: CD008020. DOI:10.1002/14651858.CD008020.pub2.

57. Abedi P, Jahanfar S, Namvar F, Lee J. Breastfeeding or nipple stimulation for reducing postpartum haemorrhage in the third stage of labour. Cochrane Database of Systematic Reviews. [Internet]. 2016, [cited 2024 February 7]. Issue 1. Art No.: CD010845. DOI:10.1002/14651858.CD010845.pub2.

58. Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews. [Internet]. 2019, [cited 2024 February 12]. Issue 4. Art No.: CDE001808. DOI:10.1002/14651858.CD001808.pub3.

59. Soltani H, Hutchon D, Poulose T. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database of Systematic Reviews. [Internet]. 2010, [cited 2024 February 15]. Issue 8. Art No.: CD006173. DOI:10.1002/14651858.CD006173.pub2.

60. Oladapo OT, Okusanya BO, Abalos E, Gallos ID, Papadopoulou A. Intravenous versus intramuscular prophylactic oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews. [Internet]. 2020, [cited 2024 February 12]. Issue 11. Art No.: CD009332. DOI:10.1002/14651858.CD009332.pub4.

61. Wu Y, Wang H, Wu QY, Liang XL, Wang J. A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor. Arch Gynecol Obstet 2020;301(3):643-53. doi:10.1007/s00404-020-05467-9.

62. Zhou YH, Xie Y, Luo YZ, Liu XW, Zhou J, Liu Q. Intramuscular versus intravenous oxytocin for the third stage of labor after vaginal delivery to prevent postpartum hemorrhage: a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2020;250:265-71. doi:10.1016/j.ejogrb.2020.04.007.

63. Phung LC, Farrington EK, Connolly M, Wilson AN, Carvalho B, Homer CSE, et al. Intravenous oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol 2021;225(3):250.e1-.e38. doi:10.1016/j.ajog.2021.04.258.

64. Tyagi A, Deep S, Salhotra R, Malhotra R, Singla A. Minimum effective dose of oxytocin bolus during the caesarean section for patients at high vs low risk of uterine atony: A non-randomized, dual-arm, dose-finding prospective trial. Indian Journal of Anaesthesia 2023;67(8):690-6. doi:10.4103/ija.ija_760_22.

65. Lee S, Cauldwell M, Wendler R. Cardiac effects of drugs used for induction of labour and prevention and treatment of postpartum haemorrhage. International Journal of Cardiology Congenital Heart Disease 2021;5:100208. doi:10.1016/j.ijcchd.2021.100208.

66. Society of Hospital Pharmacists of Australia. Australian injectable drugs handbook. 9th edition. Oxytocin. [Internet]: The Society of Hospital Pharmacists of Australia; 2024 [cited 2024 April 04]. Available from: https://aidh.hcn.com.au.

67. Baliuliene V, Vitartaite M, Rimaitis K. Prophylactic dose of oxytocin for uterine atony during caesarean delivery: A systematic review. International Journal of Environmental Research and Public Health 2021;18(9):5029. doi:10.3390/ijerph18095029.

68. Society of Hospital Pharmacists of Australia. Australian injectable drugs handbook, 9th edition. Ergometrine and ergometrine-oxytocin. [Internet]: The Society of Hospital Pharmacists of Australia; 2024 [cited 2024 April 10]. Available from: https://aidh.hcn.com.au.

69. van der Nelson H, O'Brien S, Burnard S, Mayer M, Alvarez M, Knowlden J, et al. Intramuscular oxytocin versus Syntometrine® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: A randomised double-blinded clinical trial of effectiveness, side effects and quality of life. BJOG 2021;128(7):1236-46. doi:10.1111/1471-0528.16622.

70. Australian Medicines Handbook. Ergometrine. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2024 [cited 2024 March 13]. Available from: <u>http://amhonline.amh.net.au/</u>

71. National Institute for Health and Care Excellence (NICE). Evidence reviews for uterotonics for the prevention of postpartum haemorrhage: Intrapartum care: Evidence review [M] [Internet]. 2023 [cited 2024 February 15]. Available from: www.nice.org.uk.

72. Australian Medicines Handbook. Carbetocin. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2024 [cited 2024 February 21]. Available from: <u>https://amhonline.amh.net.au</u>.

73. Widmer M, Piaggio G, Nguyen TMH, Osoti A, Owa OO, Misra S, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med 2018;379(8):743-52. doi:10.1056/NEJMoa1805489.

74. Jin XH, Li D, Li X. Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis. Medicine (Baltimore) 2019;98(47):e17911. doi:10.1097/MD.000000000017911.

75. Onwochei DN, Van Ross J, Singh PM, Salter A, Monks DT. Carbetocin reduces the need for additional uterotonics in elective caesarean delivery: a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials. Int J Obstet Anesth 2019;40:14-23. doi:10.1016/j.ijoa.2019.06.007.

76. Onwochei DN, Owolabi A, Singh PM, Monks DT. Carbetocin compared with oxytocin in non-elective cesarean delivery: a systematic review, meta-analysis, and trial sequential analysis of randomized-controlled trials. Can J Anaesth 2020;67(11):1524-34. doi:10.1007/s12630-020-01779-1.

77. Queensland Health. List of approved medicines (LAM): misoprostol effective November 2020 [Internet]. 2020 [cited 2024 March 13]. Available from: <u>https://www.health.qld.gov.au</u>.

 Australian Medicines Handbook. Misoprostol (obstetrics). [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2024 [cited 2024 June 17]. Available from: <u>https://amhonline.amh.net.au</u>.
 Drew T, Carvalho JCA. Pharmacologic prevention and treatment of postpartum hemorrhage. Current

Anesthesiology Reports 2021;11(1):37-47. doi:10.1007/s40140-021-00444-7. 80. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012. [cited 2024 March 27]. Available from: https://who.int. 81. International Federation of Gynaecology and Obstetrics. Misoprostol - only: recommended regimens 2017 [Internet]. 2017 [cited 2024 February 19]. Available from: <u>www.figo.org</u>.

82. Queensland Clinical Guidelines. Perineal care. Guideline No. MN23.30-V5-R28. [Internet]. Queensland Health. 2023. [cited 2024 March 13]. Available from: <u>https://www.health.qld.gov.au/qcg</u>.

83. Durocher J, Dzuba IG, Carroli G, Morales EM, Aguirre JD, Martin R, et al. Does route matter? Impact of route of oxytocin administration on postpartum bleeding: A double-blind, randomized controlled trial. PLoS One 2019;14(10):e0222981. doi:10.1371/journal.pone.0222981.

84. Ayala M, Nookala V, Fogel J, Fatehi M. Visual estimation of blood loss versus quantitative blood loss for maternal outcomes related to obstetrical hemorrhage. Baylor University Medical Center Proceedings 2023;36(3):341-5. doi:10.1080/08998280.2023.2187248.

85. Wiklund I, Fernández SA, Jonsson M. Midwives' ability during third stage of childbirth to estimate postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol X 2022;15:100158. doi:10.1016/j.eurox.2022.100158.

86. Ruiz MT, Azevedo NF, Resende CV, Rodrigues WF, Meneguci J, Contim D, et al. Quantification of blood loss for the diagnosis of postpartum hemorrhage: a systematic review and meta-analysis. Rev Bras Enferm 2023;76(6):e20230070. doi:10.1590/0034-7167-2023-0070.

87. American College of Obstetricians and Gynecologists (ACOG). Quantitative blood loss in obstetric hemorrhage: committee opinion. No. 794. Obstetrics and Gynecology 2019;134(6):e150-e6. doi:10.1097/aog.00000000003564.

88. Pacagnella RC, Borovac-Pinheiro A. Assessing and managing hypovolemic shock in puerperal women. Best Pract Res Clin Obstet Gynaecol 2019;61:89-105. doi:10.1016/j.bpobgyn.2019.05.012.

89. Igboke FN, Obi VO, Dimejesi BI, Lawani LO. Tranexamic acid for reducing blood loss following vaginal delivery: a double-blind randomized controlled trial. BMC Pregnancy Childbirth 2022;22(1):178. doi:10.1186/s12884-022-04462-z.

90. Henriquez D, Bloemenkamp KWM, Loeff RM, Zwart JJ, van Roosmalen JJM, Zwaginga JJ, et al. Fluid resuscitation during persistent postpartum haemorrhage and maternal outcome: A nationwide cohort study. Eur J Obstet Gynecol Reprod Biol 2019;235:49-56. doi:10.1016/j.ejogrb.2019.01.027.

91. Kietaibl S, Ahmed A, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022. Eur J Anaesthesiol 2023;40(4):226-304. doi:10.1097/EJA.000000000001803.

92. Collaborators WT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389(10084):2105-16. doi:10.1016/S0140-6736(17)30638-4.

93. Brenner A, Shakur-Still H, Chaudhri R, Muganyizi P, Olayemi O, Arribas M, et al. Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN). Current Controlled Trials in Cardiovascular Medicine 2023;24(1):782. doi:10.1186/s13063-023-07687-1.

94. Queensland Health. List of approved medicines (LAM): tranexamic acid injection effective December 2023. [Internet]. 2023 [cited 2024 February 13]. Available from: <u>https://www.health.gld.gov.au</u>.

95. Amgalan A, Allen T, Othman M, Ahmadzia HK. Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women's SSC of the ISTH. Journal of Thrombosis and Haemostasis 2020;18(8):1813-38. doi:10.1111/jth.14882.

96. Othman M, Han K, Elbatarny M, Abdul-Kadir R. The use of viscoelastic hemostatic tests in pregnancy and puerperium: review of the current evidence - communication from the women's health SSC of the ISTH. J Thromb Haemost 2019;17(7):1184-9. doi:10.1111/jth.14461.

97. Lee J, Eley VA, Wyssusek KH, Coonan E, Way M, Cohen J, et al. Baseline parameters for rotational thromboelastometry (ROTEM®) in healthy women undergoing elective caesarean delivery: a prospective observational study in Australia. Int J Obstet Anesth 2019;38:10-8. doi:10.1016/j.ijoa.2019.01.008.
 98. Jokinen S, Kuitunen A, Uotila J, Yli-Hankala A. Thromboelastometry-guided treatment algorithm in postpartum haemorrhage: a randomised, controlled pilot trial. Br J Anaesth 2023;130(2):165-74.

doi:10.1016/j.bja.2022.10.031.
99. Collins P, Abdul-Kadir R, Thachil J, Subcommittees on Women's health Issues in Thrombosis Haemostasis on Disseminated Intravascular Coagulation. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2016;14(1):205-10. doi:10.1111/jth.13174.

100. Tahitu M, Ramler PI, Gillissen A, Caram-Deelder C, Henriquez D, de Maat MPM, et al. Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. Acta Obstet Gynecol Scand 2022;101(1):145-52. doi:10.1111/aogs.14279.

101. Papadopoulou A, Parry Smith WR, Papadopoulou A, Thomas E, Tobias A, Price MJ, et al. Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews. [Internet]. 2020, [cited 2024 January 25]. Issue 11. Art No.: CD012754. DOI:10.1002/14651858.CD012754.pub2.

102. Balki M, Wong CA. Refractory uterine atony: still a problem after all these years. International Journal of Obstetric Anesthesia 2021;48:103207. doi:10.1016/j.ijoa.2021.103207.

103. de Vries PLM, Deneux-Tharaux C, Baud D, Chen KK, Donati S, Goffinet F, et al. Postpartum haemorrhage in high-resource settings: variations in clinical management and future research directions based on a comparative study of national guidelines. BJOG 2023;130(13):1639-52. doi:10.1111/1471-0528.17551.

104. eMIMS Plus. Ergometrine maleate. [Internet]: MIMS Australia; May 2023 [cited 2024 March 13]. Available from: https://app.emims.plus.

105. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007;99(S2):S160-S7. doi:10.1016/j.ijgo.2007.09.004.

106. Therapeutic Goods Administration. Australian product information - carboprost-reach (carboprost) [Internet]. 2023 [cited 2024 March 13]. Available from: <u>https://www.tga.gov.au</u>.

107. Al Moosa AM, Burad J, Jose S, Al Jabri RM. A five-year retrospective closed cohort study to find a superior anaesthetic technique for caesarean section from a haemodynamic perspective. Cureus 2023;15(12):e51000. doi:10.7759/cureus.51000.

108. Iskender C, Topcu HO, Timur H, Oskovi A, Goksu G, Sucak A, et al. Evaluation of risk factors in women with puerperal genital hematomas. J Matern Fetal Neonatal Med 2016;29(9):1435-9. doi:10.3109/14767058.2015.1051018.

109. Newnham-Hill A, Odendaal J, Hillman C. An intrapartum cervical buttonhole tear: A case report and review of rare tear pathogenesis. Case Rep Womens Health 2023;38:e00516. doi:10.1016/j.crwh.2023.e00516. 110. Salazar S, Grayson K, Tsamolias H. Cervical lacerations: A review of risks. Journal of Midwifery & Women's Health 2024;69(2):300-3. doi:10.1111/jmwh.13579.

111. Liao Y-C, Tsang LL-C, Yang T-H, Lin Y-J, Chang Y-W, Hsu TY, et al. Unscarred uterine rupture with catastrophic hemorrhage immediately after vaginal delivery: diagnosis and management of six consecutive cases. The Journal of Maternal-Fetal & Neonatal Medicine 2023;36(2):2243366-. doi:10.1080/14767058.2023.2243366.

Figueiró-Filho EA, Gomez JM, Farine D. Risk factors associated with uterine rupture and dehiscence: A cross-sectional Canadian study. Rev Bras Ginecol Obstet 2021;43(11):820-5. doi:10.1055/s-0041-1739461.
 Savukyne E, Bykovaite-Stankeviciene R, Machtejeviene E, Nadisauskiene R, Maciuleviciene R.

Symptomatic uterine rupture: A fifteen year review. Medicina 2020;56(11):1-7. doi:10.3390/medicina56110574. 114. Royal College of Obstetricians and Gynaecologists. Birth after previous caesarean birth. Guideline No. 45. [Internet]. 2015. [cited 2024 March 27]. Available from: https://rcog.org.uk.

115. Okano S, Erfan I, Eskandar O. Postpartum uterine rupture in an unscarred uterus. J Obstet Gynaecol 2016;36(3):393-4. doi:10.3109/01443615.2015.1085846.

116. Narasimhulu D, Shi S. Delayed presentation of uterine rupture postpartum. Am J Obstet Gynecol 2015;212(5):680.e1-.e2. doi:10.1016/j.ajog.2015.01.020.

117. Pararajasingam SS, Tsen LC, Onwochei DN. Uterine inversion. BJA Educ 2024;24(4):109-12. doi:10.1016/j.bjae.2024.01.004.

118. Kaur A, Singh B. Acute uterine inversion – A complication revisited. A case series and review of literature. Case Reports In Perinatal Medicine 2022;11(1). doi:10.1515/crpm-2020-0081.

119. Begley C. Physiology and care during the third stage of labour. In: Marshal JE, Raynor MD, editors. Myles' Textbook for Midwives E-Book: . 16 ed. Philadelphia: Elsevier Health Sciences; 2014. p. 395-416.

120. Perlman NC, Carusi DA. Retained placenta after vaginal delivery: risk factors and management. Int J Womens Health 2019;11:527-34. doi:10.2147/IJWH.S218933.

121. World Health Organization. Integrated management of pregnancy and childbirth. Pregnancy, childbirth, postpartum and newborn care: A guide for essential practice. 2015. [cited 2024 March 11]. Available from: https://who.int.

122. Queensland Health. Primary clinical care manual, 11th edition [Internet]. 2022 [cited 2024 June 4]. Available from: <u>https://www.health.qld.gov.au</u>.

123. Collins SL, Alemdar B, van Beekhuizen HJ, Bertholdt C, Braun T, Calda P, et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol 2019;220(6):511-26. doi:10.1016/j.ajog.2019.02.054.
124. Einerson BD, Weiniger CF. Placenta accreta spectrum disorder: updates on anesthetic and surgical management strategies. Int J Obstet Anesth 2021;46:102975. doi:10.1016/j.ijoa.2021.102975.
125. Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR. Placenta Accreta Spectrum. Am J Obstet Gynecol

2018;219(6):B2-B16. doi:10.1016/j.ajog.2018.09.042.

126. Collis RE, Kenyon C, Roberts TCD, McNamara H. When does obstetric coagulopathy occur and how do I manage it? International Journal of Obstetric Anesthesia 2021;46:102979. doi:10.1016/j.ijoa.2021.102979.
127. de Lloyd L, Jenkins PV, Bell SF, Mutch NJ, Martins Pereira JF, Badenes PM, et al. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. J Thromb Haemost 2023;21(4):862-79. doi:10.1016/j.jtha.2022.11.036.
128. Shah A, Kerner V, Stanworth SJ, Agarwal S. Major haemorrhage: past, present and future. Anaesthesia 2023;78(1):93-104. doi:10.1111/anae.15866.

129. Epstein D, Solomon N, Korytny A, Marcusohn E, Freund Y, Avrahami R, et al. Association between ionised calcium and severity of postpartum haemorrhage: a retrospective cohort study. Br J Anaesth 2021;126(5):1022-8. doi:10.1016/j.bja.2020.11.020.

130. National Blood Authority (NBA). Patient blood management guideline for adults with critical bleeding. Quick reference guide [Internet]. 2023 [cited 2024 January 29]. Available from: <u>https://www.blood.gov.au</u>.

131. Henriquez D, Caram-Deelder C, le Cessie S, Zwart JJ, van Roosmalen JJM, Eikenboom JCJ, et al. Association of timing of plasma transfusion with adverse maternal outcomes in women with persistent postpartum hemorrhage. JAMA Netw Open 2019;2(11):e1915628. doi:10.1001/jamanetworkopen.2019.15628.

132. Collis R, Guasch E. Managing major obstetric haemorrhage: pharmacotherapy and transfusion. Best Practice & Research. Clinical Anaesthesiology 2017;31(1):107-24. doi:10.1016/j.bpa.2017.02.001.

133. Carvalho M, Rodrigues A, Gomes M, Carrilho A, Nunes AR, Orfao R, et al. Interventional algorithms for the control of coagulopathic bleeding in surgical, trauma, and postpartum settings: recommendations from the Share Network Group. Clinical and Applied Thrombosis/ Hemostasis 2016;22(2):121-37. doi:10.1177/1076029614559773.

134. Collins PW, Cannings-John R, Bruynseels D, Mallaiah S, Dick J, Elton C, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth 2017;119(3):411-21. doi:10.1093/bja/aex181.

135. Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumeu F, Corouge J, Le Gouez A, et al. Early and systematic administration of fibrinogen concentrate in postpartum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. BJOG 2021;128(11):1814-23. doi:10.1111/1471-0528.16699.
136. Roberts TCD, De Lloyd L, Bell SF, Cohen L, James D, Ridgway A, et al. Utility of viscoelastography with

TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study. International journal of obstetric anesthesia 2021;47:103192-. doi:10.1016/j.ijoa.2021.103192.

137. Dias JD, Butwick AJ, Hartmann J, Waters JH. Viscoelastic haemostatic point-of-care assays in the management of postpartum haemorrhage: a narrative review. Anaesthesia 2022;77(6):700-11. doi:10.1111/anae.15662.

138. Ziegler B, Bachler M, Haberfellner H, Niederwanger C, Innerhofer P, Hell T, et al. Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FlinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study. Eur J Anaesthesiol 2021;38(4):348-57. doi:10.1097/EJA.00000000001366.

139. Winearls J, Wullschleger M, Wake E, McQuilten Z, Reade M, Hurn C, et al. Fibrinogen early in severe trauma study (FEISTY): results from an Australian multicentre randomised controlled pilot trial. Crit Care Resusc 2021;23(1):32-46. doi:10.51893/2021.1.OA3.

140. Queensland Health. Reference intervals for general chemistry, general immunoassay and blood gas analyser tests performed in chemical pathology, pathology Queensland [Internet]. 2024 [cited 2024 February 26]. Available from: https://www.health.qld.gov.au.

141. Ikeda A, Kondoh E, Chigusa Y, Mogami H, Kameyama Nakao K, Kido A, et al. Novel subtype of atonic postpartum hemorrhage: dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. The Journal of Maternal-Fetal & Neonatal Medicine 2020;33(19):3286-92. doi:10.1080/14767058.2019.1571033.

142. Greene RA, McKernan J, Manning E, Corcoran P, Byrne B, Cooley S, et al. Major obstetric haemorrhage: Incidence, management and quality of care in Irish maternity units. Eur J Obstet Gynecol Reprod Biol 2021;257:114-20. doi:10.1016/j.ejogrb.2020.12.021.

143. Cooks Medical. Bakri: postpartum balloon with rapid instillation components [Internet]. 2020 [cited 2024 March 14]. Available from: <u>https://www.cookmedical.com</u>.

144. Lee J, Wyssusek KH, Kimble RMN, Way M, van Zundert AA, Cohen J, et al. Baseline parameters for rotational thromboelastometry (ROTEM®) in healthy pregnant Australian women: a comparison of labouring and non-labouring women at term. Int J Obstet Anesth 2020;41:7-13. doi:10.1016/j.ijoa.2019.10.003.
145. Ronenson A, Shifman E, Kulikov A, Raspopin Y, Görlinger K, Ioscovich A, et al. Rotational thromboelastometry reference range during pregnancy, labor and postpartum period: A systematic review with meta-analysis. Journal of Obstetric Anaesthesia and Critical Care 2022;12(2):105-15.

doi:10.4103/JOACC.JOACC_21_22.

146. Lee J, Eley VA, Wyssusek KH, Kimble RMN, Way M, van Zundert AA. Rotational thromboelastometry (ROTEM®) in gestational diabetes mellitus and coagulation in healthy term pregnancy: A prospective observational study in Australia. Aust N Z J Obstet Gynaecol 2022;62(3):389-94. doi:10.1111/ajo.13474. 147. Lee J, Eley VA, Wyssusek KH, Kimble RMN, Way M, Cohen J, et al. The influence of obesity on coagulation in healthy term pregnancy as assessed by rotational thromboelastometry. Aust N Z J Obstet Gynaecol 2020;60(5):714-9. doi:10.1111/ajo.13141.

148. Shreeve NE, Barry JA, Deutsch LR, Gomez K, Kadir RA. Changes in thromboelastography parameters in pregnancy, labor, and the immediate postpartum period. Int J Gynaecol Obstet 2016;134(3):290-3. doi:10.1016/j.ijgo.2016.03.010.

 Scharman CD, Burger D, Shatzel JJ, Kim E, DeLoughery TG. Treatment of individuals who cannot receive blood products for religious or other reasons. Am J Hematol 2017;92(12):1370-81. doi:10.1002/ajh.24889.
 Zeybek B, Childress AM, Kilic GS, Phelps JY, Pacheco LD, Carter MA, et al. Management of the Jehovah's Witness in obstetrics and gynecology: A comprehensive medical, ethical, and legal approach. Obstet Gynecol Surv 2016;71(8):488-500. doi:10.1097/OGX.00000000000343.

151. Royal College of Surgeons. Caring for patients who refuse blood: A guide to good practice for the surgical management of Jehovah's Witnesses and other patients who decline transfusion [Internet]. 2016 [cited 2024 March 7]. Available from: <u>https://rcseng.ac.uk</u>.

152. Hawker L, Weeks A. Postpartum haemorrhage (PPH) rates in randomized trials of PPH prophylactic interventions and the effect of underlying participant PPH risk: a meta-analysis. BMC Pregnancy Childbirth 2020;20(1):107. doi:10.1186/s12884-020-2719-3.

153. Queensland Clinical Guidelines. Venous thromboembolism (VTE) prophylaxis in pregnancy and the puerperium. Guideline No. MN20.9-V7-R25. [Internet]. Queensland Health. 2020. [cited 2024 March 13]. Available from: <u>https://www.health.qld.gov.au/qcg</u>.

154. Queensland Clinical Guidelines. Safer infant sleep. Guideline No. MN22.71-V1-R27. [Internet]. Queensland Health. 2022. [cited 2024 May 29]. Available from: <u>https://www.health.qld.gov.au/qcg</u>.

155. Latt SM, Alderdice F, Elkington M, Awng Shar M, Kurinczuk JJ, Rowe R. Primary postpartum haemorrhage and longer-term physical, psychological, and psychosocial health outcomes for women and their partners in high income countries: A mixed-methods systematic review. PLoS One 2023;18(6):e0274041. doi:10.1371/journal.pone.0274041.

156. Chessman J, Patterson J, Nippita T, Drayton B, Ford J. Haemoglobin concentration following postpartum haemorrhage and the association between blood transfusion and breastfeeding: A retrospective cohort study. BMC Res Notes 2018;11(1):686. doi:10.1186/s13104-018-3800-0.

157. Crossland E WD, Bamber J, Tassell R, Besser M, Symington E, Robinson M, Thomas W, MacDonald S. Validation of clinical reference ranges for viscoelastometric assessment of haemostasis (TEG® 6S) and standard laboratory tests in obstetric patients [abstract]. [Internet]. 2022 [cited 2024 May 1]. Available from: https://abstracts.isth.org

Appendix A: Uterine atonia interventions








Image provided by the Clinical Skills Development Service, Metro North Health






Appendix B: Surgical ligation procedures







Appendix C: Prophylactic uterotonics

Consult a pharmacopeia for full details of indications, cautions, contraindications and interactions

Drug/Product	Dose/Route	Reconstitution	Maximum	Comments	
Oxytocin	Vaginal birth 10 International units IM/IV. IV injected slowly over 3–5 minutes	Nil	Repeat dose not recommended	Requires cold-chain storage Avoid rapid IV bolus	
	Caesarean section birth 3–5 International units IV over 1–2 minutes	Nil	10 International units IV as a slow bolus		
Syntometrine®	Oxytocin 5 International units/Ergometrine maleate 500 micrograms (per 1 mL) IM	Nil	Repeat dose not recommended	Requires cold-chain storage Administer with anti-emetic May cause severe hypertension Contraindicated with retained placenta, pre-eclampsia	
Carbetocin	100 micrograms IM/IV	Nil	Repeat dose not recommended	Heat-stable formulation does not require cold-chain storage Not recommended for use with GA Modified to increase half-life, duration of action and heat stability Half-life 40 minutes, compared with 3–17 minutes for oxytocin Higher index cost when compared with oxytocin	
Misoprostol	600 micrograms sub lingual	Nil	Repeat dose not recommended	Use when other uterotonics are not available Heat-stable, does not require cold-chain storage Absorbed 9–15 minutes after sublingual, oral, vaginal or rectal use Oral and sublingual routes have rapid onset Vaginal and rectal routes offer prolonged activity Can take 1–2.5 hours to increase uterine tone	

Appendix D: Drugs and blood products for PPH treatment

Consult a pharmacopeia for full details of indications, cautions, contraindications and interactions

Drug/Product	Dose/Route	Reconstitution	Maximum	Comments
Tranexamic acid	1 gram undiluted IV over 10 minutes	Nil required	If bleeding persists after 30 minutes or stops and restarts within 24 hours of first dose, can give a second 1 gram dose	Rapid administration may cause hypotension, dizziness Use infusion device/pump
	10 International units IM	Nil		May repeat as first line treatment if delayed IV access
Oxytocin	5 International units IV over 1–2 minutes	Nil	May repeat after 5 minutes to maximum dose of 10 International units	
Oxytocin	5–10 International units per hour IV via infusion pump	Oxytocin 30 International units in 500 mL sodium chloride 0.9%. Infuse at 83–167 mL/hour via infusion pump		Check for complete expulsion of placenta
Ergometrine	250–500 micrograms IV over 1–2 minutes	Dilute 250 microgram (0.5 mL) up to 5 mL with sodium chloride 0.9% (Concentration equals 50 microgram per mL)	May repeat 5 minutely to maximum dose of 1 mg	Administer with anti-emetic May cause severe hypertension Contraindicated with retained placenta, pre-eclampsia
	250-500 micrograms IM	Nil		
Misoprostol	800–1000 microgram per rectum	Nil	Repeat dose not recommended	Use when other uterotonics are not available or ineffective
Oarthannact	250 micrograms IM	Nil	May repeat after 15 minutes to maximum total dose of 2 mg (8 doses)	Manufacturer does not recommend intramyometrial —use at clinician's discretion
Carboprost	500 micrograms intramyometrial	Nil	Unknown/repeat not recommended	Commence cardiac monitoring and oxygen therapy prior to administration
Fibrinogen concentrate	3–4 gram IV at a rate not exceeding 5 mL per minute	Reconstitute with 50 mL of sterile water Swirl gently to ensure fully dissolved. Do not shake vial	Unknown	Inject slowly via IV injection or IV infusion device/pump Dose per vial approximately 1 g 1 gram of fibrinogen replacement increases fibrinogen by 0.25 g/L
Cryoprecipitate	One adult standard dose IV is equivalent to10 whole blood or four apheresis units	Stored frozen Defrost over 30 minutes before administration	Unknown	Derived from whole blood or collected via apheresis Australian Red Cross states one standard adult dose provides 3–4 g of fibrinogen; clinical experience suggests 2–3 g or less

Appendix E: PoC testing obstetric specific reference ranges

Reference ranges for	ROTEM [®] p	parameters
----------------------	----------------------	------------

	Reference range		
Parameter	Non-labouring pregnant woman ⁹⁷	Labouring women ¹⁴⁴	Non-pregnant population ¹⁴⁵
FIBTEM Parameters			
A5 (mm)	13–28	14–33	9–25
A10 (mm)	14–30	15–37	
MCF (mm)	16–34	16–40	
EXTEM Parameters			
CT (sec)	43–69	40–65	42–74
A5 (mm)	39–66	44–67	63–81
A10 (mm)	50–73	56–74	49–71
MCF (mm)	60–78	63–77	
INTEM Parameters#			
CT (sec)	115–245	118–222	137–246
A5 (mm)	38–63	43–65	

A5: amplitude (firmness) at 5 minutes; A10: amplitude at 10 minutes; CT: clotting time; MCF: maximum clot firmness *Most sensitive to heparin

Reference ranges for TEG[®] 6S parameters

Parameter	Reference range	
MA CFF	Obstetric	16.63–40.15
	Manufacturer	15–32
A10 CFF	Obstetric	18.47–37.12
	Manufacturer	15–30
R Time (min) CK	Manufacturer	4.6–9.1
MA CRT	Manufacturer	52–70
Lysis at 30 minutes (%) CRT	Manufacturer	< 2.2

Source: Adapted from Crossland et al. International Society on Thrombosis and Haemostasis 2022. Abstract: Validation of clinical reference ranges for viscoelastometric assessment of haemostasis (TEG[®] 6S) and standard laboratory tests in obstetric patient¹⁵⁷

A10: amplitude at 10 minutes; CFF: citrated TEG[®] functional fibrinogen; CK: Citrated Kaolin; CRT: citrated rapid TEG; MA: maximum amplitude

Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Leads

Professor Rebecca Kimble, Pre-Eminent Staff Specialist Obstetrics and Gynaecology, Royal Brisbane and Women's Hospital Dr Julie Lee, Staff Specialist Anaesthetics, Royal Brisbane and Women's Hospital

QCG Program Officer

Ms Leah Vekve, Clinical Midwife Consultant

Working Party Members

Ms Noor Al-Adhami, Pharmacist, Roval Brisbane and Women's Hospital Dr Gareth Ansell. Staff specialist Anaesthetist. Mater Health Services Dr Elize Bolton, Obstetrician and Gynaecologist, Bundaberg Mrs Anne Bousfield, Clinical Midwife Consultant, Roma Hospital Dr Yogesh Chadha, Obstetrician and Gynaecologist, Royal Brisbane and Women's Hospital Dr Lindsay Cochrane, Obstetrician and Gynaecologist, Caboolture Hospital Ms Allison Corcoran, Clinical Nurse, Royal Brisbane and Women's Hospital Mrs Victoria De Araujo, Clinical Midwife Consultant, Logan Hospital Ms Ashleigh Eastment, Registered Nurse/Midwife, Sunshine Coast University Hospital Professor Victoria Eley, Senior Staff Specialist, Royal Brisbane and Women's Hospital Ms Leah Hardiman, Consumer Representative, Mothers and Babies Australia Dr Natalie Kiesey-Calding, Obstetrician and Gynaecologist, Mount Isa Hospital Ms Eleanor Kitcatt, Clinical Director, Retrieval Services Queensland Mr Karl Kizur, Pharmacist, Townsville Hospital Ms Janelle Laws, Assistant Nursing and Midwifery Director - Education and Workforce, Metro North Hospital and Health Service Dr Nigel Lee, Midwifery Lecturer/Researcher, University of Queensland Dr Michelle Spanevello, Senior Staff Specialist/Deputy Director Haematology, Royal Brisbane and Women's Hospital Dr Makarla Stead, Director, Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital Ms Meghan Wischusen, Practice Development Midwife, Gold Coast University Hospital **Queensland Clinical Guidelines Team** Professor Rebecca Kimble, Director Ms Jacinta Lee, Manager Ms Stephanie Sutherns, Clinical Nurse Consultant

Ms Cara Cox, Clinical Nurse Consultant Ms Emily Holmes, Clinical Nurse Consultant Ms Jacqueline Plazina, Clinical Nurse Consultant Ms Leah Vekve, Clinical Midwife Consultant Ms Jillian Clarke, Clinical Midwife Consultant Steering Committee

Funding: This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health